documents incorporated reference portions proxy statement registrants annual meeting stockholders held may incorporated reference part iii annual report part item business general bristolmyers squibb company may referred bristolmyers squibb bms company us incorporated laws state delaware august name bristolmyers company successor new york business started bristolmyers company changed name bristolmyers squibb company result merger engaged discovery development licensing manufacturing marketing distribution sale biopharmaceutical products global basis operate one segmentbiopharmaceuticals additional information business segments see item financial statementsnote business segment information compete worldwide researchbased drug companies smaller research companies generic drug manufacturers products sold worldwide primarily wholesalers retail pharmacies hospitals government entities medical profession manufacture products united states us puerto rico six foreign countries percentage revenues significant regioncountry follows year ended december dollars millions united states europe japan china total revenues acquisitions divestitures continue transform bms leadingedge biopharmaceutical company focused exclusively discovering developing delivering innovative medicines address serious unmet medical needs transformation encompassed areas business operations part strategy divested diabetes nonpharmaceutical businesses implemented acquisition licensing strategy executed productivity transformation initiative pti divestitures included diabetes business february mead johnson december convatec august medical imaging january part acquisition licensing strategy acquired ipierian inc ipierian april amylin pharmaceuticals inc amylin august inhibitex inc inhibitex february amira pharmaceuticals inc amira september zymogenetics inc zymogenetics october medarex inc medarex september entered several license collaboration arrangements transactions allowed continue allow us focus resources behind growth opportunities drive greatest longterm value disease standpoint focused following core therapeutic areas oncology virology immunology specialty cardiovascular disease fibrosis genetically defined diseases products pharmaceutical products include chemicallysynthesized drugs small molecules increasing portion products produced biological processes typically involving recombinant dna technology called biologics small molecule drugs typically administered orally eg form pill tablet although drug delivery mechanisms used well biologics typically administered patients injections infusion revenues come products following therapeutic classes virology including human immunodeficiency virus hiv infection oncology neuroscience immunoscience cardiovascular pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity business focused innovative biopharmaceutical products rely patent rights various forms regulatory protection maintain market exclusivity products us european union eu countries patent rights forms exclusivity expire generic versions medicine approved marketed often substantial rapid declines sales original innovative product discussion patent rights regulatory forms exclusivity see intellectual property product exclusivity discussion impact generic competition business see generic competition following chart shows key products together year earliest basic exclusivity loss patent rights data exclusivity occurred currently estimated occur us eu japan china also sell pharmaceutical products countries however data provided countrybycountry basis individual country revenues significant outside us eu japan china many instances basic exclusivity loss date listed expiration date patent claims active ingredient drug method using drug approved indication one approved indication instances basic exclusivity loss date listed chart expiration date data exclusivity period situations data exclusivity without patent protection competitor could seek regulatory approval submitting clinical trial data obtain marketing approval prior expiration data exclusivity estimate market exclusivity period products purpose business planning length market exclusivity products impossible predict certainty complex interaction patent regulatory forms exclusivity inherent uncertainties regarding patent litigation assurance particular product enjoy market exclusivity full period time appears estimate exclusivity limited estimate following schedule presents revenues key products estimated basic exclusivity loss us eu japan china total revenues product past currently estimated year basic exclusivity loss dollars millions us eua japan china virology baraclude c hepatitis c franchiseb reyataz sustiva franchise e f oncology erbitux g h opdivo sprycel yervoy h h neuroscience abilify j immunoscience orencia h h cardiovascular eliquis note currently estimated earliest year basic exclusivity loss includes statutory extensions exclusivity granted instances may able obtain additional six months exclusivity product based pediatric extension certain instances may laterexpiring patents cover particular forms compositions drug well methods manufacturing methods using drug patents may sometimes result favorable market position products product exclusivity predicted assured us healthcare law enacted qualifying biologic products receive years data exclusivity biosimilar enter market described detail intellectual property product exclusivity indicates brand names products trademarks owned bms specific trademark ownership information included exhibit index currently market product country region indicated uncertainty chinas exclusivity laws resulted generic competition china market uncertainty china 's exclusivity laws references eu throughout include member states european union year ended december basic patent applications filed current member states listed products instances date basic exclusivity loss different various eu member states eu countries basic patent obtained may data protection available b exclusivity period relates daklinza daclatasvir brand c september teva pharmaceuticals launched generic version baraclude entecavir actions follow decision june us court appeals federal circuit uphold lower court decision invalidating baracludes patent february petition rehearing en banc also denied october company filed petition writ certiorari us supreme court january data exclusivity eu expired market exclusivity expires e exclusivity period relates sustiva efavirenz brand include exclusivity related combination therapy composition matter patent efavirenz us expired method use patent treatment hiv infection expired september pediatric exclusivity granted provides additional six month period exclusivity added term patents listed orange book october company announced successfully resolved outstanding us patent litigation relating efavirenz loss exclusivity us efavirenz expected occur december f exclusivity period relates sustiva brand include exclusivity related combination therapy market exclusivity sustiva expired november countries eu data exclusivity sustiva expired eu g biologic product approved biologics license application bla data exclusivity us expires patent specifically claims composition matter cetuximab active ingredient erbitux rights commercialize cetuximab terminate h exclusivity period based regulatory data protection addition anticipated loss exclusivity us commercialization rights abilify aripiprazole terminate april j eu commercialization rights abilify eu terminated june summary indication intellectual property position product partner thirdparty manufacturing arrangements products us applicable eu japan baraclude baraclude entecavir potent selective inhibitor hepatitis b virus approved us food drug administration fda treatment chronic hepatitis b virus infection baraclude discovered developed internally september teva pharmaceuticals launched generic version baraclude entecavir experienced rapid significant negative impact us net product sales baraclude beginning fourth quarter actions follow decision june us court appeals federal circuit uphold lower court decision invalidating baracludes patent february petition rehearing en banc also denied october company filed petition writ certiorari requesting us supreme court review january information patent litigation matter see item financial statementsnote legal proceedings contingencies composition matter patent expires eu japan uncertainty chinas exclusivity laws resulted generic competition china market bulk active entecavir manufactured company third party product finished facilities hepatitis c franchise daklinza daclatasvir dcv oral small molecule nsa replication complex inhibitor treatment hepatitis c virus infection hcv approved combination medicinal products eu across multiple genotypes august dual regimen sunvepra also approved japan july currently registrational process us patent covering daclatasvir composition matter expires us sunvepra asunaprevir asv oral small molecule ns protease inhibitor treatment hcv approved dual regimen dcvasv japan july october announced would pursue fda approval dual regimen withdrawn new drug application ndafor asunaprevir manufacture bulk requirements daclatasvir finish product facilities obtain bulk requirements asunaprevir thirdparty manufacturer finish product thirdparty facility reyataz franchise reyataz atazanavir sulfate protease inhibitor treatment hiv reyataz franchise includes reyataz combination therapy evotaz atazanavir mg cobicistat mg oncedaily single tablet two drug regimen combining reyataz gilead sciences inc 's gilead tybost cobicistat treatment hiv infection adults developed atazanavir worldwide license novartis pharmaceutical corporation novartis royalty paid based percentage net product sales entitled promote reyataz use combination norvir ritonavir non exclusive license agreement abbvie inc abbvie amended royalty paid based percentage net product sales licensing agreement gilead evotaz approved january market exclusivity reyataz expected expire us china major eu member countries japan data exclusivity eu expired manufacture bulk requirements atazanavir finish product facilities sustiva franchise sustiva efavirenz nonnucleoside reverse transcriptase inhibitor treatment hiv sustiva franchise includes sustiva antiretroviral drug used treatment hiv well bulk efavirenz included combination therapy atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oncedaily single tablet threedrug regimen combining sustiva gileads truvada emtricitabine tenofovir disoproxil fumarate information arrangement gilead see alliances item financial statementsnote alliances rights market efavirenz us canada uk france germany ireland italy spain licensed merck co inc merck royalty based percentage revenues efavirenz marketed another company japan composition matter patent efavirenz us expired method use patent treatment hiv infection expired september additional six month period pediatric exclusivity added term patents october company announced successfully resolved outstanding us patent litigation relating efavirenz loss exclusivity us efavirenz expected occur december market exclusivity sustiva expired november countries eu data exclusivity sustiva expired eu obtain bulk requirements efavirenz third parties produce finished goods facilities supply third parties bulk efavirenz gilead responsible producing finished atripla product erbitux erbitux cetuximab igg monoclonal antibody designed exclusively target block epidermal growth factor receptor egfr expressed surface certain cancer cells multiple tumor types well normal cells erbitux biological product approved combination irinotecan treatment patients egfrexpressing metastatic colorectal cancer mcrc failed irinotecanbased regimen monotherapy patients intolerant irinotecan fda approved erbitux use combination radiation therapy treatment locally regionally advanced squamous cell carcinoma head neck single agent treatment patients recurrent metastatic squamous cell carcinoma head neck prior platinumbased therapy failed fda also approved erbitux firstline recurrent locoregional metastatic head neck cancer combination platinumbased chemotherapy fluorouracil exclusive distribution rights north america cetuxmab granted company imclone systems incorporated imclone predecessor company imclone llc whollyowned subsidiary eli lilly company lilly part alliance lilly information alliance lilly see alliances item financial statementsnote alliances data exclusivity erbitux us expires patent specifically claims composition matter cetuximab active molecule erbitux erbitux approved fda health authorities monotherapy use patent use erbitux combination fluorouracil antineoplastic agent approved fda combination use claimed granted us patent expires including granted patent term extension use patent challenged yeda research development company ltd yeda pursuant december worldwide settlement agreement sanofi yeda granted imclone nonexclusive worldwide license use patent data exclusivity japan expires yeda right license use patent third parties granted amgen inc amgen license amgen received fda approval market egfrproduct competes erbitux yedas license patent third parties could result product competition erbitux might otherwise occur unable assess potential impact competition obtain finished goods requirements cetuximab use north america lilly lilly manufactures bulk requirements cetuximab facilities filling finishing performed third party bms oversight responsibility description supply agreement lilly see manufacturing quality assurance opdivo opdivo nivolumab fully human monoclonal antibody binds programmed death receptor pd nkt cells investigated anticancer treatment phase iii trials commenced nonsmall cell lung cancer renal cell cancer melanoma jointly patent ono pharmaceutical co ltd ono covering opdivo composition matter expires us excluding potential patent term extension december fda approved opdivo unresectable inoperable metastatic melanoma disease progression following yervoy braf v mutation positive braf inhibitor opdivo also approved japan july indication fda granted fast track designation opdivo three tumor types non small cell lung cancer renal cell carcinoma metastatic melanoma registrational process melanoma nonsmall cell lung cancer us europe fda granted breakthrough therapy designation hodgkin lymphoma obtain bulk requirements opdivo third party finish product facilities sprycel sprycel dasatinib multitargeted tyrosine kinase inhibitor approved firstline treatment adults philadelphia chromosome positive chronic myeloid leukemia chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib mesylate gleevec trademark novartis sprycel internally discovered part alliance otsuka information alliance otsuka pharmaceutical co ltd otsuka see alliances item financial statementsnote alliances patent term extension granted us extending term basic composition matter patent covering dasatinib june company entered settlement agreement apotex regarding patent infringement suit covering monohydrate form dasatinib whereby apotex launch generic dasatinib monohydrate abbreviated new drug application anda product september earlier certain circumstances us orphan drug exclusivity expired protected product generic applications currently approved orphan indications majority eu countries composition matter patent covering dasatinib expires april excluding potential term extensions composition matter patent expires japan china manufacture bulk requirements dasatinib finish product facilities yervoy yervoy ipilimumab biological product monoclonal antibody treatment patients unresectable metastatic melanoma yervoy approved us march eu july currently also studied indications including lung cancer well adjuvant melanoma hormonerefractory prostate cancer information research development yervoy see research development yervoy discovered medarex codeveloped company medarex subsidiary patent covering ipilimumab composition matter currently expires us eu excluding potential patent term extensions data exclusivity expires us eu bulk ipilimumab manufactured company third party product finished facilities third party facility abilify abilify aripiprazole atypical antipsychotic agent adult patients schizophrenia bipolar mania disorder major depressive disorder abilify also pediatric uses schizophrenia bipolar disorder among others global commercialization agreement otsuka excluding japan china certain asian countries information arrangement otsuka see alliances item financial statementsnote alliances basic us composition matter patent covering aripiprazole term current abilify agreement expires april including granted patent term extension six month pediatric extension composition matter patent force major eu countries original expiration date extended grant supplementary protection certificate eu countries data exclusivity rights commercialize eu expired june obtain bulk requirements aripiprazole otsuka company otsuka finish product facilities orencia orencia abatacept biological product fusion protein novel immunosuppressive activity targeted initially adult patients moderately severely active rheumatoid arthritis inadequate response certain currently available treatments orencia available intravenous subcutaneous formulation us europe japan series patents covering abatacept method use us patent term extension granted one composition matter patents extending term us patent eu composition matter patent covering abatacept expired majority eu countries applied supplementary protection certificates also pediatric extension supplementary protection certificates protection protection certificates granted data exclusivity expires us eu japan bulk abatacept manufactured company third party finish formulations product facilities see alliances discussion collaborations ono orencia japan eliquis eliquis apixaban oral factor xa inhibitor targeted stroke prevention atrial fibrillation prevention treatment venous thromboembolic vte disorders apixaban discovered internally part alliance pfizer inc pfizer information alliance pfizer see item financial statementsnote alliances composition matter patent covering apixaban us expires february excluding potential patent term extensions eu expires applied supplementary protection certificates supplementary protection certificates granted expire data exclusivity eu expires apixaban manufactured company third party product finished facilities research development invest heavily research development rd believe critical longterm competitiveness major rd facilities new jersey connecticut research development also carried various facilities throughout world including belgium uk india sites us supplement internal drug discovery development programs alliances collaborative agreements help us bring new products pipeline drug development engage services physicians hospitals medical schools research organizations worldwide conduct clinical trials establish safety effectiveness new products management continues emphasize leadership innovation productivity quality strategies success research development activities concentrate research development efforts following disease areas significant unmet medical needs immunooncology oncology immunoscience cardiovascular virology fibrotic diseases genetically defined diseases also continue analyze may selectively pursue promising leads areas addition discovering developing new molecular entities look ways expand value existing products new indications formulations provide additional benefits patients order new drug reach market industry practice government regulations us eu foreign countries provide determination drugs effectiveness safety preclinical tests controlled clinical evaluation clinical development potential new drug includes phase phase ii phase iii clinical trials designed specifically support new drug application particular indication assuming trials successful phase clinical trials involve small number healthy volunteers patients suffering indicated disease test safety proper dosing phase ii clinical trials involve larger patient population investigate side effects efficacy optimal dosage drug candidate phase iii clinical trials conducted confirm phase ii results significantly larger patient population longer term provide reliable conclusive data regarding safety efficacy drug candidate rd process typically takes fourteen years longer approximately three years often spent phase iii latestage development consider rd programs phase iii significant rd programs programs include investigational compounds phase iii development initial indications marketed products phase iii development additional indications formulations drug development time consuming expensive risky average one chemical compounds discovered pharmaceutical industry researchers proves medically effective safe enough become approved medicine drug candidates fail stage process even latestage product candidates sometimes fail receive regulatory approval according kmr group based industry success rates approximately compounds enter phase development fail achieve regulatory approval failure rate compounds enter phase ii development approximately compounds enter phase iii development approximately total research development expenses include costs discovery research preclinical development early latestage clinical development drug formulation well postcommercialization medical support marketed products proportionate allocations enterprisewide costs appropriate costs research development spending billion billion billion includes payments thirdparty collaborations contracts end employed approximately people rd activities including substantial number physicians scientists holding graduate postgraduate degrees higherskilled technical personnel manage rd programs portfolio basis investing resources stage research development early discovery latestage development continually evaluate portfolio rd assets ensure appropriate balance earlystage latestage programs support future growth company spending latestage development programs represented approximately annual rd expenses last three years individual investigational compound marketed product represented rd expenses last three years listed latestage investigational compounds phase iii clinical trials regulatory review least one potential indication whether investigational compounds ultimately becomes one marketed products depends results clinical studies competitive landscape potential products market manufacturing processes necessary produce potential product commercial scale among factors however noted assurance seek regulatory approval compounds approval sought obtained also assurance compound approved commercially successful stage development determine intellectual property issues patent protection may may available investigational compounds patent coverage highlighted includes patent terms patent term extensions granted beclabuvir beclabuvir oral small molecule nonnucleoside nsb inhibitor phase iii development commenced treatment hcv patent covering beclabuvir composition matter expires us elotuzumab elotuzumab humanized monoclonal antibody investigated anticancer treatment discovered pdl biopharma part alliance abbvie phase iii trials commenced multiple myeloma fda granted breakthrough therapy designation elotuzumab use combination lenalidomide dexamethasone treatment multiple myeloma patients received one prior therapies abbvie owns patent covering elotuzumab composition matter expires us bms bms investigational compound studied hiv shown antiviral activity hiv infected individuals attachment inhibitors distinct mode action entry inhibitors prevent entry hiv host cell following attachment bms prodrug metabolized active basic compound hold patent covering bms composition matter expires november us terminated phase iii development peginterferon lambda treatment hepatitis c virus following table lists potential additional indications andor formulations key marketed products potentially registrational trials currently regulatory review key marketed product potential indication andor formulation hepatitis c franchise combination antivirals treatment hcv reyataz pediatric extension opdivo additional indications melanoma nonsmall cell lung cancer hematology renal cell carcinoma head neck cancer additional indications melanoma renal cell carcinoma glioblastoma combination yervoy yervoy additional indications adjuvant melanoma prostate cancer nonsmallcell lung cancer small cell lung cancer additional indications melanoma renal cell carcinoma glioblastoma combination opdivo orencia additional indications lupus nephritis psoriatic arthritis autoinjector device following key developments currently expected occur respect significant pipeline programs outcome timing expected developments dependent upon number factors including among things availability data outcome certain clinical trials acceptance presentations certain medical meetings andor actions health authorities undertake obligation publicly update information whether result new information future events otherwise hepatitis c franchise data available clinical trials potential approval us daclatasvir opdivo potential approval lung cancer us eu potential approval melanoma eu data available clinical trials including data phase iii study lung cancer potential submissions various tumors based registrational trials yervoy potential approval adjuvant melanoma data available phase iii studies prostate lung cancer potential submissions various tumors based registrational trials elotuzumab data available phase iii study multiple myeloma alliances enter alliances third parties transfer rights develop manufacture market andor sell pharmaceutical products owned parties alliances include licensing arrangements codevelopment comarketing agreements copromotion arrangements joint ventures alliances involve sharing research development costs risk incurring research development expenses compounds lead revenuegenerating products reduced however profitability alliance products generally lower profits alliance products shared alliance partners actively pursue arrangements view alliances important complement discovery development commercialization activities alliances third parties rights manufacture market andor sell pharmaceutical products contain customary early termination provisions typically found agreements kind generally based partys material breach bankruptcy voluntary involuntary product safety concerns amount notice required early termination generally ranges immediately upon notice days receipt notice termination immediately upon notice generally available party files voluntary bankruptcy petition material safety issue arises product medical riskbenefit incompatible welfare patients continue develop commercialize product termination upon days notice generally available involuntary bankruptcy petition filed dismissed material breach party occurred cured number alliance agreements also permit alliance partner us terminate without cause typically exercisable substantial advance written notice often exercisable specified period time elapsed alliance agreement signed alliances typically otherwise contain provisions provide party right terminate alliance short notice general retain rights product brought alliance another party partys intellectual property alliance terminates loss rights one products marketed sold us pursuant alliance could material results operations cash flows could material financial condition liquidity customary pharmaceutical industry terms alliances generally coextensive exclusivity period may vary countrybycountry basis significant current alliances currently marketed products investigational compounds described current marketed productsinlicensed otsuka maintain worldwide commercialization agreement otsuka codevelop copromote abilify abilify agreement excluding certain asian countries us portion agreement amended expires upon expected loss product exclusivity april agreement expired european union eu countries june nonus country exclusive right sell abilify agreement expires later april loss exclusivity country detailed description share revenues expenses abilify see item financial statements note alliances us portion abilify agreement oncology agreement described include changeofcontrol provision acquired acquiring company competing product abilify new company assume abilify agreement amended oncology agreement currently exists acquiring company product competes abilify otsuka elect request acquiring company choose whether divest abilify competing product scenario abilify divested otsuka would obligated acquire rights abilify agreement amended price according predetermined schedule agreements also provide event generic competitor abilify option terminating abilify april amendment agreement previously amended remaining force exercise option either would receive payment otsuka according pre determined schedule oncology agreement would terminate time ii oncology agreement would continue truncated period according predetermined schedule early termination abilify agreement immediate upon notice case voluntary bankruptcy ii minimum payments made otsuka iii first commercial sale occurred within three months receipt necessary approvals days material breach occurred cured commencement cure occurred within days notice material breach days case involuntary bankruptcy petition filed dismissed addition termination available otsuka upon days notice event challenge otsukas patent rights marketbymarket basis event market product direct competition abilify upon termination expiration abilify agreement retain rights abilify discussion oncology agreement otsuka see current marketed productsinternally discovered discussion alliance otsuka see item financial statementsnote alliances gilead joint ventures gilead develop commercialize atripla us canada europe company gilead share responsibility certain activities related commercialization atripla us canada throughout eu certain european countries gilead recognizes atripla revenues us canada countries europe alliance revenues recognized atripla include bulk efavirenz component atripla calculated differently eu us following loss exclusivity sustiva eu alliance revenues deferred related alliance receivable recognized atripla sold thirdparty customers collaboration agreement governing commercialization atripla us canada continue terminated mutual agreement parties otherwise described event material breach one party collaboration agreement nonbreaching party may terminate agreement breaching party cure material breach parties agree desirable practicable withdraw combination product markets commercialized time one generic versions partys component products launched us party right terminate collaboration agreement control joint venture commercialization combination product us canada however three years terminated party continue receive percentage net product sales based contribution bulk components atripla otherwise retains rights products europe following loss exclusivity sustiva effective january percentage atripla net sales europe recognized bms equal difference average net selling prices atripla truvada alliance continue europe either party terminates arrangement last patent expiration occurs atripla truvada sustiva entered licensing agreement gilead develop commercialize fixeddose combination containing reyataz gileads cobicistat pharmacoenhancing boosting agent increases blood levels certain hiv medicines potentially allow one pill daily dosing april company filed new drug application nda fda combination treatment evotaz atazanavir mg cobicistat mg approved fda january discussion alliance gilead see item financial statementsnote alliances lilly egfr commercialization agreement lilly lillys subsidiary imclone codevelopment copromotion erbitux us canada japan egfr agreement respect erbitux net product sales north america lilly receives distribution fee based flat rate net product sales north america plus reimbursement certain royalties paid lilly company lilly share one half profits losses evenly japan merck kgaa receiving half profits losses japan parties share royalties payable third parties pursuant formula set forth commercialization agreement purchase north american commercial requirements bulk erbitux lilly agreement expires erbitux north america september early termination available based material breach effective days notice material breach material breach cured commencement cure occurred upon six months notice us exists significant concern regarding regulatory patient safety issue would seriously impact longterm viability product upon termination expiration alliance retain rights erbitux north america shared codevelopment copromotion rights erbitux merck kgaa japan agreement signed october lilly merck kgaa merck japan erbitux received marketing approval japan july use erbitux treating patients advanced recurrent colorectal cancer head neck cancer december december bms agreed transfer cocommercialization rights japan merck kgaa may exchange future royalties included income earned discussion alliance lilly see item financial statementsnote alliances current marketed productsinternally discovered otsuka simultaneously extension abilify agreement april company otsuka entered oncology agreement sprycel ixempra ixabepilone includes us japan eu markets oncology territory beginning fee paid otsuka annually based percentages annual net product sales sprycel ixempra oncology agreement expires respect sprycel ixempra includes changeofcontrol provision acquired abilify agreement described discussion abilify agreement otsuka see current marketed productsinlicensed discussion alliance otsuka see item financial statementsnote alliances addition january granted otsuka exclusive rights japan develop commercialize onglyza agreement entitled receive milestone payments based certain regulatory events well salesbased payments following regulatory approval onglyza japan retained rights copromote onglyza otsuka japan otsuka responsible development costs japan june otsuka assigned rights onglyza exception specific transition services kyowa hakko kirin khk part consent assignment bms waived rights copromote onglyza japan february sold astrazeneca diabetes business comprised global alliance including rights ownership onglyza seeitem financial statementsnote alliances discussion astrazeneca january entered worldwide except japan codevelopment cocommercialization agreement astrazeneca onglyza saxagliptin agreement farxiga sglt agreement bms astrazeneca pharmaceuticals lp whollyowned subsidiary astrazeneca entered alliance regarding worldwide development commercialization amylins portfolio products including bydureon byetta symlin kombiglyze codeveloped astrazeneca saxagliptin agreement exclusive rights develop sell onglyza japan licensed otsuka december june assigned otsuka khk described february sold astrazeneca diabetes business comprised global alliance including rights ownership onglyza farxiga bydureon byetta symlin myalept astrazeneca terminated existing alliance agreements connection sale entered several new agreements including transitional services agreement supply agreement development agreement supply agreement continue manufacture onglyza kombiglyze farxiga discussion alliance astrazeneca see item financial statementsnote alliances investigational compounds development internally discovered pfizer company pfizer parties worldwide codevelopment cocommercialization agreement eliquis anticoagulant discovered us prevention treatment atrial fibrillation vte disorders pfizer funds development costs depending study companies share commercialization expenses profits losses equally global basis discussion alliance pfizer see item financial statementsnote alliances ono bms ono alliance agreement develop commercialize opdivo antipd human monoclonal antibody investigated anticancer treatment bms exclusive right develop manufacture commercialize opdivo territories worldwide except japan south korea taiwan ono responsible development commercialization prior amendment discussed ono entitled receive royalties following regulatory approvals territories excluding three countries listed royalty rates north america applicable territories alliance agreement amended july provide additional collaboration activities japan south korea taiwan pertaining opdivo several bms compounds including ipilimumab lirilumab urelumab bms antilag parties right obligation jointly develop commercialize compounds bms responsible supply product profits losses development costs shared equally combination therapies involving compounds parties otherwise sharing activities involving one partys compounds bms ono also codevelop cocommercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulations jointly promoted parties assigned customer accounts bms responsible product supply copromotion fee paid party sale made partys assigned customer alliances may bms reckitt benckiser group plc reckitt entered three year alliance regarding several overthecounterproducts sold primarily mexico brazil reckitt received right sell distribute market products may certain responsibilities related regulatory matters covered territory bms receives royalties net product sales exclusively supplies certain products reckitt pursuant supply agreement cost plus markup certain limited assets including market authorizations certain employees directly attributed business transferred reckitt start alliance period bms retained ownership assets related business including trademarks covering products bms also granted reckitt option acquire trademarks inventory certain assets exclusively related products end alliance period price determined based multiple sales plus cost remaining inventory held bms time april alliance modified provide option reckitt purchase bms manufacturing facility located mexico primarily dedicated products included alliance options exercised together substantially employees facility expected transferred reckitt option exercised option exercised assets previously transferred reckitt revert back bms option may exercised reckitt may november case closing would expected occur may february bms medicines company entered two year alliance regarding recothrom recombinant thrombin use topical hemostat control nonarterial bleeding surgical procedures previously acquired bms connection acquisition zymogenetics inc medicines company received right sell distribute market recothrom global basis two years certain responsibilities related regulatory matters covered territory bms exclusively supplied recothrom medicines company pursuant supply agreement cost plus markup received royalties net product sales recothrom certain employees directly attributed business certain assets transferred medicines company start alliance period including recothrom bla related regulatory assets bms retained assets related recothrom including patents trademarks inventory bms also granted medicines company option acquire patents trademarks inventory certain assets exclusively related recothrom price determined based multiple sales plus cost remaining inventory held bms time medicines company exercised option acquired business million february please see item financial statementsnote alliances information regarding alliance investigational compounds developmentinlicensed abbvie august granted exclusive rights pdl biopharma inc abbvie elotuzumab humanized monoclonal antibody investigated treatment multiple myeloma terms collaboration fund development costs elotuzumab upon commercialization abbvie share profits losses us paid tiered royalties outside us solely responsible commercialization elotuzumab addition abbvie may receive milestone payments us based certain regulatory events sales thresholds achieved licensing arrangements addition alliances described inlicensing outlicensing arrangements respect inlicenses agreements novartis reyataz merck efavirenz among others also certain compounds outlicensed third parties development commercialization including obtained acquisitions entitled receive milestone payments compounds move regulatory process royalties based net product sales products commercialized intellectual property product exclusivity license number patents us foreign countries primarily covering products also developed many brand names trademarks products consider overall protection patents trademarks licenses intellectual property rights material value act protect rights infringement pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity products market exclusivity generally determined two forms intellectual property patent rights held innovator company regulatory forms exclusivity innovative drug entitled patents key determinant market exclusivity branded pharmaceuticals patents provide innovator right exclude others practicing invention related medicine patents may cover among things active ingredients various uses drug product pharmaceutical formulations drug delivery mechanisms processes intermediates useful manufacture products protection individual products extends varying periods accordance expiration dates patents various countries protection afforded may also vary country country depends upon type patent scope coverage availability meaningful legal remedies country market exclusivity also sometimes influenced regulatory intellectual property rights many developed countries provide certain nonpatent incentives development medicines example us eu japan certain countries regulatory intellectual property rights offered incentives research medicines rare diseases orphan drugs medicines useful treating pediatric patients incentives extend market exclusivity period product beyond patent term us eu japan china also provide minimum period time approval new drug regulatory agency may rely upon innovators data approve competitors generic copy data protection regions china however questionable whether data protection laws enforceable certain markets patent protection forms market exclusivity may expired data protection particular importance however regulatory forms exclusivity prevent competitor gaining regulatory approval prior expiration regulatory data exclusivity basis competitors safety efficacy data drug even drug identical marketed innovator specific aspects law governing market exclusivity data protection pharmaceuticals vary country country following summarizes key exclusivity rules markets representing significant sales united states us key products protected patents varying terms depending type patent filing date significant portion products patent life however lost time takes innovative company develop obtain regulatory approval new drug compensation least part lost patent term innovator may depending number factors extend expiration date one patent maximum term five years provided extension cause patent effect years date drug approval company seeking market innovative pharmaceutical us must submit complete set safety efficacy data fda innovative pharmaceutical chemical company files nda medicine biological product biologics license application bla filed type application filed affects regulatory exclusivity rights chemical products competitor seeking launch generic substitute chemical innovative drug us must file anda fda anda generic manufacturer needs demonstrate bioequivalence generic substitute approved nda drug anda relies upon safety efficacy data previously filed innovator nda innovator company required list certain patents covering medicine fda commonly known orange book absent successful patent challenge fda approve anda innovators listed patents expire however innovator marketed product four years generic manufacturer may file anda allege one patents listed orange book innovators nda either invalid infringed allegation commonly known paragraph iv certification innovator must decide whether file patent infringement suit generic manufacturer time time andas including paragraph iv certifications filed respect certain products evaluate andas casebycase basis warranted file suit generic manufacturer protect patent rights addition benefiting patent protection certain innovative pharmaceutical products receive periods regulatory exclusivity nda designated orphan drug receive seven years exclusivity orphan indication time period neither ndas andas drug product approved orphan use company may also earn six months additional exclusivity drug specific clinical trials conducted written request fda study use medicine treat pediatric patients submission fda made prior loss basic exclusivity medicines approved nda also receive several types regulatory data protection innovative chemical pharmaceutical entitled five years regulatory data protection us competitors file fda approval generic substitutes innovators patent challenged described generic manufacturer may file anda fourth year fiveyear data protection period pharmaceutical drug product contains active ingredient previously approved nda approved new formulation drug new indication basis new clinical trials receives three years data protection formulation indication biologic products us healthcare legislation enacted created approval pathway biosimilar versions innovative biological products previously exist prior time innovative biologics essentially unlimited regulatory exclusivity new regulatory mechanism fda approve products similar generic copies innovative biologics basis less extensive data required full bla innovator marketed product four years manufacturer may file application approval biosimilar version innovator product however although application approval biosimilar may filed four years approval innovator product qualified innovative biological products receive years regulatory exclusivity meaning fda may approve biosimilar version years innovative biological product first approved fda law also provides mechanism innovators enforce patents protect innovative biological products biosimilar applicants challenge patents patent litigation may begin early four years innovative biological product first approved fda us increased likelihood generic biosimilar challenges innovators intellectual property increased risk loss innovators market exclusivity first generic companies increasingly sought challenge innovators basic patents covering major pharmaceutical products second statutory regulatory provisions us limit ability innovator company prevent generic biosimilar drugs approved launched patent litigation ongoing result developments possible predict length market exclusivity particular product certainty based solely expiration relevant patents current forms regulatory exclusivity european union patents pharmaceutical products generally enforceable eu us may extended compensate patent term lost regulatory review process extensions granted countrybycountry basis primary route use obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part marketing authorization application maa european medicines agency ema ema evaluates maa provides recommendation european commission ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states obtaining marketing authorization approval company must obtain pricing reimbursement pharmaceutical product typically subject member state law certain eu countries process take place simultaneously product marketed eu countries process must completed company market new product pricing reimbursement procedure take months sometimes years complete throughout eu products marketing authorizations filed octobernovember subject regime eight years innovator received first community authorization medicinal product generic company may file marketing authorization application product health authorities marketing authorization application approved generic company may commercialize product either years elapsed initial marketing authorization granted innovator possible extension years available innovator first eight years marketing authorization obtains additional indication significant clinical benefit comparison existing treatments products filed prior octobernovember year period data protection centralized procedures period either six years mutual recognition procedure depending member state contrast us patents eu listed regulatory authorities generic versions pharmaceutical products approved data protection expires regardless whether innovator holds patents covering drug thus possible innovator may seeking enforce patents generic competitor already marketing product also european patent system opposition procedure generic manufacturers may challenge validity patents covering innovator products within nine months grant general eu law treats chemicallysynthesized drugs biologicallyderived drugs respect intellectual property data protection addition relevant legislation annexes related biologic medicinal products ema issued guidelines outline additional information provided biosimilar products also known generic biologics order review application marketing approval japan japan medicines new chemical entities generally afforded eight years data exclusivity approved indications dosage patents pharmaceutical products enforceable generic copies receive regulatory approval data exclusivity patent expirations us patents japan may extended compensate patent term lost regulatory review process general japanese law treats chemicallysynthesized biologicallyderived drugs respect intellectual property market exclusivity china china medicines new chemical entities generally afforded six years data exclusivity approved indications dosage uncertainty chinas exclusivity laws resulted generic competition china market generic copies receive regulatory approval data exclusivity patent expirations currently unlike us china patent term restoration compensate patent term lost regulatory process general chinese law treats chemicallysynthesized biologicallyderived drugs respect intellectual property market exclusivity rest world countries outside us eu japan china wide variety legal systems respect intellectual property market exclusivity pharmaceuticals developed countries utilize systems similar either us eu among developing countries adopted patent laws andor regulatory exclusivity laws others developing countries formally adopted laws order comply world trade organization wto commitments taken steps implement laws meaningful way enforcement wto actions long process governments assurance outcome thus assessing likely future market exclusivity innovative drugs developing countries take account formal legal rights political factors well marketing distribution customers promote appropriate use products directly healthcare professionals providers doctors nurse practitioners physician assistants pharmacists technologists hospitals pharmacy benefit managers pbms managed care organizations mcos also provide information appropriate use products consumers us directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceuticals see government regulation price constraints field sales medical organizations explain risks benefits approved uses products medical professionals work gain access products formularies reimbursement plans lists recommended approved medicines products including medicare part plans providing information clinical profiles products marketing sales prescription pharmaceuticals limited approved uses particular product continue develop scientific data information products provide information response unsolicited inquiries doctors medical professionals managed care organizations operations include several marketing sales organizations product marketing organization supported sales force may responsible selling one products also marketing organizations focus certain classes customers managed care entities certain types marketing tools digital consumer communications sales forces focus communicating information new products new uses well established products promotion physicians increasingly targeted physician specialists treat patients need medicines products sold principally wholesalers lesser extent directly distributors retailers hospitals clinics government agencies pharmacies gross revenues three largest pharmaceutical wholesalers us percentage global gross revenues follows mckesson corporation cardinal health inc amerisourcebergen corporation us business inventory management agreements imas substantially direct wholesaler distributor customers allow us monitor us wholesaler inventory levels requires wholesalers distributors maintain inventory levels one month demand imas including three largest wholesalers expired december company negotiated extensions imas three largest wholesalers march continuing discussions certain us wholesaler customers extending renewing agreements periods beyond current expiration number defined countries outside us established full scale distributor model make medically necessary drugs available patients continue marketing authorization trademarks products contracted services fullservice distributor provide distribution logistics regulatory pharmacovigilance sales advertising promotion certain products contracts clearly define terms conditions along services provide supply firm order period monitor incountry sales forecasts ensure reasonable inventory levels products sale maintained fully continuously meet demand products within distributors territory responsibility sales distributorbased countries represented approximately companys total revenues competition markets compete generally broad based highly competitive compete worldwide researchbased drug companies many smaller research companies limited therapeutic focus generic drug manufacturers important competitive factors include product efficacy safety ease use price demonstrated costeffectiveness marketing effectiveness product labeling customer service research development new products processes sales products impacted new studies indicate competitors product safer effective treating disease particular form disease one products revenues also impacted additional labeling requirements relating safety convenience may imposed products fda similar regulatory agencies different countries competitors introduce new products processes therapeutic cost advantages products subject progressive price reductions decreased volume sales generic competition one biggest competitive challenges face generic pharmaceutical manufacturers us eu regulatory approval process exempts generics costly timeconsuming clinical trials demonstrate safety efficacy allowing generic manufacturers rely safety efficacy innovator product result generic pharmaceutical manufacturers typically invest far less research development researchbased pharmaceutical companies therefore price products significantly lower branded products accordingly branded product loses market exclusivity normally faces intense price competition generic forms product upon expiration loss market exclusivity product lose major portion revenues product short period time rate revenues decline product expiration exclusivity varies country general decline us market rapid developed countries though observed rapid declines number eu countries well also declines developed countries tend rapid developing countries rate revenues decline expiration exclusivity also historically influenced product characteristics example drugs used large patient population eg prescribed key primary care physicians tend experience rapid declines drugs specialized areas medicine eg oncology drugs complex manufacture eg sterile injectable products usually experience slower decline simpler manufacture certain countries outside us patent protection weak nonexistent must compete generic versions shortly launch innovative products addition generic pharmaceutical companies may introduce generic product exclusivity expired resolution related patent litigation information market exclusivity see intellectual property product exclusivity believe longterm competitive position depends upon success discovering developing innovative costeffective products serve unmet medical needs together ability manufacture products efficiently market effectively highly competitive environment managed care organizations growth mcos us also major factor healthcare marketplace half us population participates version managed care mcos include medical insurance companies medical plan administrators healthmaintenance organizations medicare part prescription drug plans alliances hospitals physicians physician organizations organizations consolidating fewer larger entities thus enhancing purchasing strength importance us successfully compete business mcos must often demonstrate products offer medical benefits also cost advantages compared forms care new products introduce compete products already market products later developed competitors noted generic drugs exempt costly timeconsuming clinical trials demonstrate safety efficacy often lower costs brandname drugs mcos focus primarily immediate cost drugs often favor generics reason many governments also encourage use generics alternatives brandname drugs healthcare programs laws us generally allow many cases require pharmacists substitute generic drugs rated government procedures essentially equivalent brandname drug substitution must made unless prescribing physician expressly forbids exclusion product formulary lead sharply reduced usage mco patient population consequently pharmaceutical companies compete aggressively products included possible companies compete inclusion based upon unique features products greater efficacy better patient ease use fewer side effects lower overall cost therapy also important factor products demonstrate fewer therapeutic advantages must compete inclusion based primarily price generally although universally successful major products included mco formularies government regulation price constraints pharmaceutical industry subject extensive global regulation regional country state local agencies federal food drug cosmetic act fdc act federal statutes regulations various state statutes regulations laws regulations foreign governments govern varying degrees testing approval production labeling distribution postmarket surveillance advertising dissemination information promotion products lengthy process laboratory clinical testing data analysis manufacturing development regulatory review necessary required governmental approvals extremely costly significantly delay product introductions given market promotion marketing manufacturing distribution pharmaceutical products extensively regulated major world markets addition operations subject complex federal state local foreign environmental occupational safety laws regulations anticipate laws regulations affecting manufacture sale current products introduction new products continue require substantial scientific technical effort time expense well significant capital investments particular importance fda us jurisdiction virtually activities imposes requirements covering testing safety effectiveness manufacturing labeling marketing advertising postmarketing surveillance products many cases fda requirements increased amount time money necessary develop new products bring market us fda mandates drugs manufactured packaged labeled conformity current good manufacturing practices cgmp established fda complying cgmp regulations manufacturers must continue expend time money effort production recordkeeping quality control ensure products meet applicable specifications requirements ensure product safety efficacy fda periodically inspects drug manufacturing facilities ensure compliance applicable cgmp requirements failure comply statutory regulatory requirements subjects us possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experiences use products must reported fda could result imposition market restrictions labeling changes product removal product approvals may withdrawn compliance regulatory requirements maintained problems concerning safety efficacy occur following approval federal government extensive enforcement powers activities pharmaceutical manufacturers including authority withdraw delay product approvals commence actions seize prohibit sale unapproved noncomplying products halt manufacturing operations compliance cgmps impose seek injunctions voluntary recalls civil monetary criminal penalties restriction prohibition sales withdrawal approval products marketed us could materially adversely affect business financial condition results operations cash flows marketing authorization products subject revocation applicable governmental agencies addition modifications enhancements approved products changes manufacturing locations many circumstances subject additional fda approvals may may received may subject lengthy application process distribution pharmaceutical products subject prescription drug marketing act pdma part fdc act regulates activities federal state level pdma implementing regulations states permitted require registration manufacturers distributors provide pharmaceuticals even manufacturers distributors place business within state states also permitted adopt regulations limiting distribution product samples licensed practitioners pdma also imposes extensive licensing personnel recordkeeping packaging quantity labeling product handling facility storage security requirements intended prevent sale pharmaceutical product samples product diversions fda amendments act imposed additional obligations pharmaceutical companies delegated enforcement authority fda area drug safety key elements legislation give fda authority require companies conduct postmarketing safety studies drugs impose certain drug labeling changes relating safety mandate risk mitigation measures education healthcare providers restricted distribution medicines require companies publicly disclose data clinical trials prereview television advertisements marketing practices us pharmaceutical manufacturers subject federal state healthcare laws used protect integrity government healthcare programs office inspector general us department health human services oig oversees compliance applicable federal laws connection payment products government funded programs primarily medicaid medicare laws include federal antikickback statute criminalizes offering something value induce recommendation order purchase products services reimbursed government healthcare program oig issued series guidances segments healthcare industry including compliance program guidance pharmaceutical manufacturers oig guidance includes recommendation pharmaceutical manufacturers minimum adhere phrma code voluntary industry code marketing practices subscribe phrma code implemented compliance program address requirements set forth oig guidance compliance healthcare laws failure comply healthcare laws could subject us administrative legal proceedings including actions federal state government agencies actions could result imposition civil criminal sanctions may include fines penalties injunctive remedies impact could materially adversely affect business financial condition results operations cash flows also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission department justice department health human services us also licensed us drug enforcement agency procure produce controlled substances therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies activities outside us also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing products regulatory requirements vary country country whether fda approval approval ec obtained product approval product comparable regulatory authorities countries outside us eu case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required us approval one country assure product approved another country many markets outside us operate environment governmentmandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs andor enacted acrosstheboard price cuts methods cost control eu countries example government regulates pricing new product launch often direct price controls international price comparisons controlling profits andor reference pricing markets uk germany government set pricing restrictions launch pricing freedom subsequently limited operation profit price control plan uk operation reference price system germany companies also face significant delays market access new products mainly france spain italy belgium two years elapse new medicines become available national markets additionally member states eu regularly imposed new additional cost containment measures pharmaceuticals recent years italy example imposed mandatory price decreases existence price differentials within eu due different national pricing reimbursement laws leads significant parallel trade flows us healthcare industry subject various governmentimposed regulations authorizing prices price controls continue impact total revenues participate state government medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities also participate government programs specify discounts certain government entities significant us department defense us department veterans affairs entities receive minimum discounts based defined nonfederal average manufacturer price purchases march us government enacted healthcare reform legislation signing law patient protection affordable care act hr reconciliation bill containing package changes healthcare bill legislation makes extensive changes current system healthcare insurance benefits intended broaden coverage reduce costs bills significantly change americans receive healthcare coverage pay also significant impact companies particular companies pharmaceutical industry healthcare related industries including bms experienced continue experience additional financial costs certain changes business new healthcare law implemented example minimum rebates medicaid drug sales increased percent percent medicaid rebates also extended drugs used riskbased medicaid managed care plans addition extend discounts certain critical access hospitals cancer hospitals covered entities required expansion b drug pricing program public health service act beginning also required provide percent discount brandname drugs patients fall within medicare part coverage gap also referred donut hole also required pay annual nontaxdeductible fee federal government based allocation market share branded prior year sales certain government programs including medicare medicaid department veterans affairs department defense tricare discussion rebates programs see item managements discussion analysis financial condition results operationstotal revenues critical accounting policies sources availability raw materials general purchase raw materials supplies required production products open market products purchase raw materials supplies one source source available us single source approved source among many available us thereby requiring us obtain raw materials supplies particular source attempt possible mitigate raw material supply risks inventory management alternative sourcing strategies discussion sourcing see manufacturing quality assurance discussions particular products manufacturing quality assurance meet expected product demand operate manage manufacturing network including thirdparty contract manufacturers inventory related thereto manner permits us improve efficiency maintaining flexibility reallocate manufacturing capacity pharmaceutical production processes complex highly regulated vary widely product product given shifting adding manufacturing capacity lengthy process requiring significant capital expenditures well regulatory approvals maintain operate flexible manufacturing network consisting internal external resources minimize unnecessary product transfers inefficient uses manufacturing capacity discussion regulatory impact manufacturing see government regulation price constraints pharmaceutical manufacturing facilities located us puerto rico france italy ireland japan mexico china require significant ongoing capital investment maintenance compliance increasing regulatory requirements addition product line changes next several years expect continue modification existing manufacturing network meet complex processing standards may required newly introduced products including biologics biologics manufacturing involves complex processes traditional pharmaceutical operations fda approved large scale multiproduct bulk biologics manufacturing facility devens massachusetts may continue make capital investments facility also announced plans build new largescale biologics manufacturing facility cruiserath ireland rely third parties manufacture supply us portion active ingredients necessary us manufacture various products including baraclude sustiva franchise erbitux yervoy reyataz abilify orencia eliquis beginning february following sale diabetes business astrazeneca astrazeneca assumed manufacturing responsibilities bydureon byetta maintain stable supply products take variety actions including inventory management maintenance additional quantities materials possible designed provide reasonable level ingredients held thirdparty supplier us manufacturing operations interrupted additional protection cases take steps maintain approved backup source available example rely capacity devens massachusetts facility capacity available thirdparty contract manufacturers manufacture orencia thirdparty manufacturer rely existing future products unable maintain stable supply products operate sufficient capacity meet order requirements comply government regulations manufacturing pharmaceuticals meet complex processing requirements biologics business performance prospects could negatively impacted additionally thirdparty suppliers experience extended plant shutdowns substantial unplanned increases demand suspension manufacturing regulatory reasons could experience interruption supply certain products product shortages production could resumed expanded connection divestitures licensing arrangements distribution agreements certain products certain circumstances entered agreements agreed supply products third parties addition liabilities could arise failure supply products agreements arrangements could require us invest facilities production nonstrategic products result additional regulatory filings obligations cause interruption manufacturing products success depends great measure upon customer confidence quality products integrity data support safety effectiveness product quality arises total commitment quality parts operations including research development purchasing facilities planning manufacturing distribution maintain qualityassurance procedures relating quality integrity technical information production processes control production processes involves detailed specifications ingredients equipment facilities manufacturing methods processes packaging materials labeling perform tests various stages production processes final product ensure product meets regulatory requirements standards tests may involve chemical physical chemical analyses microbiological testing combination along analyses quality control provided business unitsite quality assurance groups monitor existing manufacturing procedures systems used us subsidiaries thirdparty suppliers environmental regulation facilities operations subject extensive us foreign laws regulations relating environmental protection human health safety including governing discharges pollutants air water use management disposal hazardous radioactive biological materials wastes cleanup contamination pollution controls permits required many operations permits subject modification renewal revocation issuing authorities environment health safety group monitors operations around world providing us overview regulatory requirements overseeing implementation standards compliance also incur operating capital costs matters ongoing basis expended approximately million million million capital projects undertaken specifically meet environmental requirements addition invested projects reduce resource use energy water although believe substantial compliance applicable environmental health safety requirements permits required operations nevertheless could incur additional costs including civil criminal fines penalties cleanup costs thirdparty claims property damage personal injury violations liabilities laws many current former facilities operation many years time operators facilities generated used stored disposed substances wastes considered hazardous federal state andor foreign environmental laws including us comprehensive environmental response compensation liability act cercla result soil groundwater certain facilities may contaminated may required make significant expenditures investigate control remediate contamination cases provide compensation andor restoration damages natural resources currently involved investigation remediation current former facilities also identified potentially responsible party prp applicable laws environmental conditions approximately former waste disposal reprocessing facilities operated third parties investigation andor remediation activities ongoing may face liability cercla federal state foreign laws entire cost investigation remediation contaminated sites natural resource damages regardless fault ownership time disposal release addition certain sites bear remediation responsibility pursuant contractual obligations generally thirdparty operator sites involving multiple prps liability expected apportioned based nature amount hazardous substances disposed party site number financially viable prps additional information matters see item financial statementsnote legal proceedings contingencies employees december employed approximately people foreign operations significant operations outside us conducted subsidiaries distributors geographic breakdown total revenues see table captioned geographic areas item financial statementsnote business segment information discussion total revenues geographic area see item managements discussion analysis financial condition results operationstotal revenues international operations subject certain risks inherent conducting business abroad including limited currency fluctuations possible nationalization expropriation price exchange controls counterfeit products limitations foreign participation local enterprises restrictive governmental actions international businesses also subject governmentimposed constraints including laws pricing reimbursement use products depending direction change relative us dollar foreign currency values increase decrease reported dollar value net assets results operations change foreign exchange rates net unfavorable impact growth rate revenues predict certainty future changes foreign exchange rates effect growth rate revenues attempt mitigate impact operational means using various financial instruments see discussions item quantitative qualitative disclosures market risk item financial statementsnote financial instruments fair value measurements bristolmyers squibb website internet website address wwwbmscom website make available free charge annual quarterly current reports including amendments reports soon reasonably practicable electronically file material furnish material us securities exchange commission sec information relating corporate governance bristolmyers squibb including standards business conduct ethics code ethics senior financial officers code business conduct ethics directors collectively codes corporate governance guidelines information concerning executive committee board directors including board committees committee charters transactions bristolmyers squibb securities directors executive officers available website investorscorporate governance caption print stockholder upon request waivers codes directors executive officers material amendment code business conduct ethics directors code ethics senior financial officers posted promptly website information relating stockholder services including dividend reinvestment plan direct deposit dividends available website investorsstockholder services caption addition information sustainability programs available website responsibility caption incorporate reference certain information parts proxy statement annual meeting stockholders sec allows us disclose important information referring manner please refer information proxy statement annual meeting stockholders annual report available website investorssec filings caption march item risk factors factors described could significantly negatively affect business prospects financial condition operating results credit ratings could cause trading price common stock decline additional risks uncertainties presently known us risks currently consider immaterial could also impair operations financial condition face intense competition manufacturers including innovative medicines lowerpriced generic products bms dependent uptake market expansion marketed brands new product introductions new indications product extensions copromotional activities alliance partners deliver future growth competition major global challenge includes lowerpriced generics increasingly aggressive generic commercialization tactics ii lower prices companies ' products real perceived superior efficacy benefit safety risk profiles differentiating factors iii technological advances patents attained competitors iv clinical study results products competitors products affect value proposition products v business combinations among competitors major customers vi competing interests external partnerships develop bring new products markets could also experience limited blocked market access due real perceived differences value propositions products compared competitors could lose market exclusivity product earlier expected pharmaceutical biotechnology industries majority innovative products commercial value realized market exclusivity period us countries market exclusivity expires generic versions approved marketed biosimilars introduced even competing product usually substantial rapid declines products revenues market exclusivity products based upon patent rights certain regulatory forms exclusivity scope patent rights varies country country may also dependent availability meaningful legal remedies country failure obtain patent intellectual property rights limitations use loss rights could material us countries including certain eu member states basic patent protections products may exist certain countries historically offer right obtain specific types patents andor licensors file markets addition patent environment unpredictable validity enforceability patents predicted certainty absent relevant patent protection product data exclusivity period expires generic versions approved marketed generic biosimilar product manufacturers also increasingly seeking challenge patents expire could face earlierthanexpected competition products time patents covering key products likely continue subject patent litigation cases manufacturers may seek regulatory approval submitting clinical trial data obtain marketing approval choose launch generic product risk expiration applicable patents andor final resolution related patent litigation example experienced rapid significant negative impact us baraclude net product sales fourth quarter due launch generic entecavir following federal courts decision invalidate composition matter patent february assurance particular product enjoy market exclusivity full time period appears estimates disclosed addition countries india allowing competitors manufacture sell competing generic products known compulsory licensing negatively impacts protections afforded company lowerpriced biosimilars bms biologic products competing biologics could introduce new competition key products potentially impacting volumes prices increased pricing pressure restrictions us abroad managed care organizations institutional purchasers government agencies programs among others could negatively affect revenues profit margins products continue subject increasing pressures across portfolio market access pricing rebates restrictions us eu regions around world including rules practices managed care organizations institutional governmental purchasers ii judicial decisions governmental laws regulations medicare medicaid us healthcare reform including patient protection affordable care act iii potential impact pharmaceutical reimbursement medicare part formularies product pricing general iv delays gaining reimbursement v government price erosion mechanisms across europe countries resulting deflation pharmaceutical product pricing vi collection delays governmentfunded public hospitals outside us vii impact pricing parallel trade across borders viii developments technology andor industry practices could impact reimbursement policies practices thirdparty payers ix limited blocked market access due real perceived differences value propositions products compared competing products may experience difficulties delays development commercialization new products compounds products may appear promising development fail reach market within expected optimal timeframe addition product extensions additional indications may approved developing commercializing new compounds products include inherent risks uncertainties including due efficacy safety concerns delayed denied regulatory approvals delays challenges producing products commercial scale excessive costs manufacture ii failure enter implement optimal alliances development andor commercialization new products iii failure maintain consistent scope variety promising latestage products iv failure one products achieve maintain commercial viability v changes regulatory approval processes may cause delays denials new product approvals regulatory approval delays especially common product expected risk evaluation mitigation strategy required fda address significant riskbenefit issues inability bring product market significant delay expected approval related launch date new product could negatively impact revenues earnings addition certain acquired pipeline programs including inprocess research development iprd cancelled believe commercial prospects reduced may recognize material noncash impairment charges programs finally losing key molecules intermediaries compound library natural manmade disaster act sabotage could negatively impact product development cycle thirdparty royalties represent significant percentage pretax income operating cash flow entered several arrangements entitle us potential royalties third parties outlicensed intellectual property commercialization rights salesbased contingent proceeds related divestiture businesses many arrangements minimal continuing involvement contribute financial success activities royalties continued represent increasing percentage pretax income including royalties related sanofi alliance outlicensed intellectual property contingent proceeds resulting divestiture diabetes business pretax income generated royalties approximately million pretax income could adversely affected royalty streams decline future periods failure execute business strategy could adversely impact growth profitability may able consistently maintain rich pipeline internal rd programs transactions third parties support future revenue growth competition among pharmaceutical companies acquisition product licensing opportunities intense may able locate suitable acquisition targets licensing partners reasonable prices successfully execute transactions also may able successfully realize expected efficiencies effectiveness changes structure operations diversified specialty biopharmaceuticals strategy unable support grow marketed products successfully execute launches newly approved products advance latestage pipeline manage change transformational issues manage costs effectively operating results financial condition could negatively impacted failure attract retain highly qualified personnel could affect ability successfully develop commercialize products success largely dependent continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization competition qualified personnel biopharmaceutical field intense sure able attract retain quality personnel costs materially increase public announcement data clinical studies news developments related latestage immunooncology compounds likely cause significant volatility stock price development key immunooncology compounds whether alone part combination therapy delayed discontinued stock price could decline significantly focusing efforts resources certain disease areas focused portfolio investors placing heightened scrutiny late stage compounds particular opdivo important asset immunooncology portfolio announced multiple regulatory milestones opdivo fully human monoclonal antibody investigated anticancer treatment nonsmalllung cancer renal cell cancer melanoma along tumor types alone combination approved cancer products yervoy expect receive news ongoing clinical trials health authorities announcement data clinical studies news developments related latestage immunooncology compounds nivolumab likely cause significant volatility stock price furthermore announcement negative unexpected data discontinuation development key immunooncology compounds whether alone part combination therapy delay anticipated timelines filing regulatory approval likely cause stock price decline significantly assurance data clinical studies support filing regulatory approval even approved key immunooncology compounds become commercially successful businesses acquire future may underperform may able successfully integrate existing business may continue support pipeline compounds products obtained licensing acquisitions future revenues profits cash flows acquired companys products technologies pipeline candidates may materialize due lower product uptake delayed missed pipeline opportunities inability capture expected synergies increased competition safety concerns regulatory issues supply chain problems factors beyond control substantial difficulties costs delays could result integrating acquisitions including rd manufacturing distribution sales marketing promotion information technology activities ii policies procedures processes controls compliance iii company cultures iv compensation structures human resource activities v tax considerations depend several key products revenues cash flows earnings historically derived majority revenue earnings several key products heavily dependent one two products past years dependence profitability products likely continue instance abilify revenues billion represented revenues orencia sprycel revenues totaled billion billion represented revenues respectively lose rights abilify us international markets april expect growth products yervoy eliquis opdivo become increasing important part revenue base reduction revenues one products could significantly negatively impact revenues cash flows earnings changes us foreign laws regulations may negatively affect revenues profit margins could become subject new government laws regulations could negatively affect business operating results financial condition company additional healthcare reform initiatives us countries including additional mandatory discounts fees ii increasing tax revenues us countries means reduce debt changing tax rates limiting phasingout eliminating deductions tax credits modifying tax collection processes taxing certain tax havens taxing certain excess income intellectual property changing rules earnings repatriations changing tax laws iii new laws regulations judicial governmental decisions affecting pricing drug reimbursement receivable payments access marketing within across jurisdictions iv changes intellectual property law v changes accounting standards vi increasing data privacy regulations enforcement vii emerging new global regulatory requirements reporting payments value transfers healthcare professionals viii potential impact importation restrictions legislative andor regulatory changes product labeling changes marketed products could result negative impact revenues regulatory authorities may need change labeling pharmaceutical product including product marketed several years changes often result additional data postmarketing studies headtohead trials adverse events reports studies identify biomarkers objective characteristics indicate particular response product therapy studies postmarketing experience produce important additional information product new information added products label affect riskbenefit profile leading potential recalls withdrawals declining revenue well product liability claims sometimes additional information studies identifies portion patient population may nonresponsive medicine would higher risk adverse reactions labeling changes based studies may limit patient population studies providing additional information may sponsored us could also sponsored competitors insurance companies government institutions managed care organizations scientists investigators interested parties additional safety efficacy information studies assist us healthcare providers identifying best patient population product also negatively impact revenues due inventory returns limited patient population going forward additionally certain study results especially headtohead trials could affect products formulary listing could also adversely affect revenues could experience difficulties delays manufacturing distribution sale products product supply related patient access could negatively impacted among things product seizures recalls forced closings manufacturing plants ii disruption supply chain continuity including natural manmade disasters one facilities critical supplier well failure failure suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing iii manufacturing quality assurancequality control supply problems governmental approval delays iv failure sole source single source supplier provide us necessary raw materials supplies finished goods within reasonable timeframe v failure thirdparty manufacturer supply us bulk active finished product time vi construction regulatory approval delays new facilities expansion existing facilities including intended support future demand biologics products vii failure meet new emerging regulations requiring products tracked throughout distribution channels using unique identifiers verify authenticity supply chain viii manufacturing distribution issues including limits manufacturing capacity due regulatory requirements changes types products produced biologics physical limitations business interruptions adverse outcomes legal matters could negatively affect business current future lawsuits claims proceedings government investigations could preclude delay commercialization products could adversely affect operations profitability liquidity financial condition possible insurance recoveries available legal matters include intellectual property disputes ii adverse decisions litigation including product liability commercial cases iii antibribery regulations us foreign corrupt practice act uk antibribery act iv recalls withdrawals pharmaceutical products forced closings manufacturing plants v failure fulfill obligations supply contracts government customers vi product pricing promotional matters vii lawsuits claims asserting investigations violations securities antitrust federal state pricing consumer protection data privacy laws viii environmental health safety sustainability matters iv tax liabilities depend third parties meet contractual regulatory obligations rely suppliers vendors outsourcing partners alliance partners third parties research develop manufacture commercialize copromote sell products manage certain marketing selling human resource finance information technology business unit functional services meet contractual regulatory obligations third parties located markets subject political social risk corruption infrastructure problems natural disasters addition country specific privacy data security risk given current legal regulatory environments failure critical third party meet obligations including future royalty milestone payments adequately deploy business continuity plans event crisis andor satisfactorily resolve significant disagreements us address factors could material adverse impact companys operations results addition third parties violate alleged violated laws regulations including local pharmaceutical code us foreign corrupt practice act uk bribery act similar laws regulations performance obligations us possible could suffer financial reputational harm negative outcomes including possible legal consequences increasingly dependent information technology systems infrastructure face certain risks including cyber security data leakage significant breakdown invasion corruption destruction interruption critical information technology systems infrastructure workforce others authorized access systems unauthorized persons could negatively impact operations everincreasing use evolution technology including cloudbased computing creates opportunities unintentional dissemination intentional destruction confidential information stored systems nonencrypted portable media storage devices could also experience business interruption information theft confidential information reputational damage industrial espionage attacks malware cyber attacks may compromise system infrastructure lead data leakage either internally thirdparty providers although aggregate impact operations financial condition material date target events nature expect continue invested industry appropriate protections monitoring practices data information technology reduce risks continue monitor systems ongoing basis current potential threats assurance however efforts prevent breakdowns breaches thirdparty providers databases systems could adversely affect business social media platforms present risks challenges inappropriate andor unauthorized use certain media vehicles could cause brand damage information leakage could lead legal implications including improper collection andor dissemination personally identifiable information employees patients healthcare professionals stakeholders addition negative inaccurate posts comments us social networking website could damage reputation brand image goodwill disclosure nonpublic companysensitive information workforce others external media channels could lead information loss might structured processes place secure protect information identifying new points entry social media continues expand presents new challenges adverse changes us global regional local economic conditions could adversely affect profitability global economic risks pose significant challenges companys growth profitability difficult mitigate worlds major economies hold historicallyhigh debt levels many experiencing slow growth high unemployment rates several risks lie ahead including management us debt european sovereign debt significant operations europe including manufacturing exposure customer credit risks europe including governmentguaranteed hospital receivables markets payments received time addition future pension plan funding requirements continue sensitive global economic conditions related impact equity markets also exposed commercial risks economic factors control could pose significant challenges underlying profitability changes foreign currency exchange interest tax rates could material adverse effect operating results liquidity significant operations outside us generating approximately revenues revenues earnings cash flow exposed risk strengthening us dollar euro japanese yen chinese renminbi canadian dollar south korean among others difficult mitigate example february us dollar strengthened euro approximately japanese yen approximately compared average rates derivative financial instruments used hedge certain underlying economic exposures financial instruments used including derivatives subject counterparty credit risk addition results operations could negatively impacted member country exiting eu also exposed changes interest rates ability access money markets andor capital markets could impeded adverse liquidity market conditions occur debt ratings would pressured financial clinical expectations met illegal distribution sale third parties counterfeit versions products stolen products could negative impact reputation business third parties may illegally distribute sell counterfeit versions products meet rigorous manufacturing testing standards patient receives counterfeit drug may risk number dangerous health consequences reputation business could suffer harm result counterfeit drugs sold brand name addition thefts inventory warehouses plants intransit properly stored later sold unauthorized channels could adversely impact patient safety reputation business item b unresolved staff comments none item properties world headquarters located park avenue new york ny lease approximately square feet floor space lease approximately properties countries manufacture products worldwide locations owned us manufacturing locations aggregate square feet floor space geographic area follows december number locations square feet united states europe rest world total portions manufacturing locations properties owned leased us us elsewhere used research development administration storage distribution information properties see item businessmanufacturing quality assurance item legal proceedings information pertaining legal proceedings found item financial statementsnote legal proceedings contingencies incorporated reference herein item mine safety disclosures applicable part ia executive officers registrant listed information executive officers february executive officers elected board directors initial term continues first board meeting following next annual meeting stockholders thereafter elected oneyear term successors elected executive officers serve pleasure board directors name current position age employment history past years lamberto andreotti president chief operating officer director company chief executive officer director present chief executive officer director company member senior management team charles bancroft chief financial officer company executive vice president chief financial officer present executive vice president chief financial officer company member senior management team giovanni caforio md senior vice president oncology us global commercialization chief operating officer director senior vice president oncology immunology global commercialization member senior management team president us pharmaceuticals executive vice president chief commercial officer present chief operating officer director company joseph c caldarella vice president corporate controller senior vice president corporate controller present senior vice president corporate controller francis cuss mb bchir frcp senior vice president discovery exploratory clinical research executive vice president chief scientific officer senior vice president research member senior management team present executive vice president chief scientific officer john e elicker vice president investor relations senior vice president public affairs investor senior vice president investor relations relations present senior vice president public affairs investor relations member senior management team ann powell judge chief human resources officer shire pharmaceuticals senior vice president global human resources present senior vice president global human resources member senior management team sandra leung general counsel corporate secretary executive vice president general counsel present executive vice president general counsel corporate secretary corporate secretary member senior management team samuel j moed senior vice president worldwide strategy operations senior vice president strategic planning senior vice president strategy analysis present senior vice president strategic planning analysis member senior management team anne nielsen vice president associate general counsel senior vice president chief compliance senior vice president deputy general counsel ethics officer present senior vice president chief compliance ethics officer member senior management team louis schmukler senior vice president specialtybiotechnology operating unit pfizer president global manufacturing supply present president global manufacturing supply member senior management team paul von autenried vice president chief information officer senior vice president enterprise services chief senior vice president chief information officer information officer present senior vice president enterprise services chief information officer member senior management team part ii item market registrants common stock stockholder matters market prices bristolmyers squibb common stock traded new york stock exchange nyse symbol bmy quarterly summary high low market prices presented high low high low common first quarter second quarter third quarter fourth quarter holders common stock number record holders common stock december number record holders based upon actual number holders registered books date include holders shares street names persons partnerships associations corporations entities identified security position listings maintained depository trust companies dividends board directors declared following quarterly dividends per share paid periods indicated common preferred first quarter second quarter third quarter fourth quarter december board directors declared quarterly dividend per share common stock paid february shareholders record january board directors also declared quarterly dividend per share preferred stock payable march shareholders record february unregistered sales equity securities use proceeds following table summarizes surrenders equity securities month period ended december total number shares approximate dollar value average price purchased part shares may yet total number paid publicly announced purchased period shares purchaseda per sharea plans programsb plans programsb dollars millions except per share data january february march three months ended march april may june three months ended june july august september three months ended september october november december three months ended december twelve months ended december reflects shares common stock surrendered company satisfy tax withholding obligations connection vesting awards longterm incentive program b may board directors authorized repurchase billion common stock june board directors increased authorization repurchase common stock additional billion repurchase program expiration date may consider future repurchases item selected financial data five year financial summary amounts millions except per share data income statement dataa total revenues continuing operations net earnings net earnings attributable noncontrolling interest bms net earnings per common share attributable bms basic diluted average common shares outstanding basic diluted cash dividends paid bms common preferred stock cash dividends declared per common share financial position data december cash cash equivalents marketable securitiesb total assets longterm debtc equity discussion items affected comparability results years see item managements discussion analysis financial condition results operationsnongaap financial measures b includes current noncurrent marketable securities c includes current portion longterm debt item managements discussion analysis financial condition results operations executive summary bristolmyers squibb company may referred bristolmyers squibb bms company us global specialty biopharmaceutical company whose mission discover develop deliver innovative medicines help patients prevail serious diseases continue evolve business leading diversified specialty biopharma company evolution accelerated result diabetes business divestiture continued focus certain therapeutic areas including immunooncology following provides brief summary certain key events discussed detail throughout report opdivo approved us japan unresectable metastatic melanoma announced positive results certain studies melanoma lung hodgkin lymphoma renal cell carcinoma several clinical collaborations also entered us seek opportunities strategically combine opdivo targeted agents dozen tumor types eliquis obtained important label extension received regulatory approvals hepatitis c franchise including daklinza eu dual regimen daklinza sunvepra japan several business development transactions completed advance pipeline therapeutic areas including fibrosis genetically defined diseases also expanding biologics manufacturing capacity devens massachusetts announced plans build new facility ireland revenues decreased result diabetes business divestiture exclusivity losses expiration rights partially offset higher sales key products including recently launched products certain markets focus optimize global brands key markets accelerated growth several key products eliquis sales increased million following global launch yervoy sales increased million continued penetration us communitybased setting first line indication improved access internationally hepatitis c franchise sales million following launches japan certain eu countries expect products continue grow along orencia sprycel recently launched opdivo partially offset revenue reductions resulting expiration certain rights pertaining abilify us royalty alliance agreements exclusivity losses baraclude us changes foreign currency rates higher pension research development related charges contributed reduction gaap eps nongaap eps increased proceeds diabetes divestiture increased cash marketable securities billion highlights following table summarizes financial information year ended december dollars millions except per share data total revenues total expenses earnings income taxes provision forbenefit income taxes effective taxbenefit rate net earnings attributable bms gaap nongaap diluted earnings per share gaap nongaap cash cash equivalents marketable securities nongaap financial measures including nongaap earnings related eps information adjusted exclude specified items represent certain costs expenses gains losses items impacting comparability financial results detailed listing specified items information reconciliations nongaap financial measures see nongaap financial measures strategy continue transform bms leading diversified specialty biopharma company focused exclusively discovering developing delivering innovative medicines address serious unmet medical needs continue evolve driven fundamental objective grow marketed products progress pipeline developing new medicines following core therapeutic areas oncology virology immunooncology specialty cardiovascular disease fibrosis genetically defined diseases pioneering innovative medicines area immunooncology unlock bodys immune system battle cancer yervoy ipilimumab first immunooncology agent introduced treatment metastatic melanoma announced multiple regulatory milestones us european union eu opdivo nivolumab investigational pd immune checkpoint inhibitor continue invest significantly deep pipeline innovative medicines covering broad array cancers entered several collaboration agreements research develop opdivo approved investigational oncology agents combination regiments evolving commercial model growing marketed product portfolio manner consistent overall strategy oncology building success yervoy yielded revenues approximately billion products sprycel dasatinib erbitux cetuximab beyond oncology remain strongly committed eliquis apixaban launched globally via alliance pfizer inc pfizer eliquis received regulatory approval us eu treatment deep vein thrombosis dvt pulmonary embolism pe adults among related indications also continue support key brands virology franchise reyataz atazanavir sulfate baraclude entecavir achieved several regulatory milestones hepatitis c portfolio launched daklinza daclatasvir sunvepra asunaprevir dual regimen japan launched daklinza eu addition continue invest orencia abatacept accounted approximately billion revenues looking ahead continue implement biopharma strategy driving growth key brands executing new product launches investing pipeline focusing prioritized markets increasing investments biologics manufacturing capabilities maintaining culture continuous improvement pursuing disciplined capital allocation including business development product pipeline developments rd programs managed portfolio basis early discovery latestage development continually evaluate portfolio ensure appropriate balance earlystage latestage programs support future growth rd programs phase iii development considered significant programs constitute latestage development pipeline development programs include investigational compounds phase iii development initial indications marketed products phase iii development additional indications formulations spending programs represents approximately annual rd expenses individual investigational compound marketed product represented rd expenses last three years latestage development programs could potentially impact revenue earnings within next years although expect latestage development programs make market following recent significant developments marketed products latestage pipeline opdivo nivolumab fully human monoclonal antibody binds programmed death receptor pd nkt cells investigated anticancer treatment opdivo part alliance ono unresectable inoperable metastatic advanced melanoma december company announced us food drug administration fda approved opdivo treatment unresectable metastatic melanoma disease progression following yervoy ipilimumab braf v mutation positive braf inhibitor indication approved accelerated approval based tumor response rate durability response continued approval indication may contingent upon verification description clinical benefit confirmatory trials november company announced results checkmate phase iii randomized double blind study comparing opdivo chemotherapy dacarbazine dtic patients treatment nave braf wildtype advanced melanoma n study met primary endpoint overall survival os median os reached opdivo versus months dtic oneyear survival rate opdivo versus dtic decrease risk death patients treated opdivo hazard ratio death hr p survival advantage also observed opdivotreated patients pdl positive pdl negative patients september company announced results checkmate phase iii randomized controlled openlabel study opdivo versus investigators choice chemotherapy icc patients advanced melanoma previously treated yervoy based planned interim analysis coprimary endpoint objective response rate ci opdivo arm n ci icc reference arm n patients least six months follow september european medicines agency ema validated review marketing authorization application maa opdivo advanced melanoma application also granted accelerated assessment emas committee medicinal products human use chmp june company announced randomized blinded comparative phase iii study evaluating opdivo versus dacarbazine patients previously untreated braf wildtype advanced melanoma checkmate stopped early analysis conducted independent data monitoring committee dmc showed evidence superior os patients receiving opdivo compared control arm patients trial unblinded allowed cross opdivo june company announced follow results phase ib doseranging trial evaluating safety activity combination regimen opdivo yervoy given either concurrently sequentially patients advanced melanoma study n additional year follow cohort received concurrent combination regimen opdivo mgkg plus yervoy mgkg n oneyear os rate twoyear os rate doses used ongoing phase ii phase iii melanoma trials checkmate new safety signals reported concurrent combination cohorts additional follow n may company announced updated survival data advanced melanoma cohort n expanded phase ib doseranging study opdivo administered single agent study results showed sustained activity heavily pretreated patient population defined two threeyear survival rates respectively across dose cohorts nonsmall cell lung cancer january company announced openlabel randomized phase iii study evaluating opdivo versus docetaxel previously treated patients advanced squamous cell nonsmall cell lung cancer nsclc stopped early assessment conducted independent dmc concluded study met endpoint demonstrating superior os patients receiving opdivo compared control arm company share data first time indicate survival advantage antipd immune checkpoint inhibitor lung cancer health authorities october company announced results checkmate phase ii singlearm openlabel study opdivo administered single agent patients advanced squamous cell nsclc progressed least two prior systemic treatments receiving three prior therapies n approximately months minimum follow objective response rate studys primary endpoint ci assessed independent review committee irc using recist criteria median duration response reached estimated oneyear survival rate ci median overall survival mos months ci september ema validated review maa opdivo advanced squamous cell nsclc first completed regulatory submission pd immune checkpoint inhibitor tumor type may company announced results phaseb study evaluating safety efficacy opdivo single agent patients advanced squamous cell nsclc previously treated study phase b study evaluating opdivo single agent chemotherapynave patients checkmate study twoyear survival rate across doses n previouslytreated patients received opdivo single agent highest patients received mgkg dose n checkmate overall response rate pdl positive tumors pdl negative tumors chemotherapynave patients received opdivo single agent n types treatmentrelated serious adverse events saes checkmate consistent opdivo trials patients experiencing grade treatmentrelated saes checkmate multiarm study evaluating opdivo monotherapy combination agents april company met fda regarding results study evaluated opdivo thirdline squamous cell nsclc initiated rolling submission indication based study company completed rolling submission december indications december company announced results cohort patients ongoing phase b trial checkmate evaluated opdivo patients relapsed refractory hematological malignancies n results showed high levels response patients relapsed refractory classical hodgkin lymphoma hl overall response rate n stable disease n may company announced fda granted opdivo breakthrough therapy designation treatment patients hl failure autologous stem cell transplant brentuximab may company announced results phase ii phase ib study opdivo patients advanced metastatic renal cell carcinoma phase ii checkmate doseranging trial n overall response rates opdivo single agent ranged oneyear survival rate ranged patients received prior antiangiogenic treatment phase b checkmate trial overall response rate investigational combination regimen opdivo yervoy n ranged week progression free survival rate ranged previously treated treatmentnave patients hepatitis c portfolio daklinza daclatasvir dcv nsa replication complex inhibitor sunvepra asunaprevir asv ns protease inhibitor beclabuvir bcv nsb nonnucleoside polymerase inhibitor development february fda notified company intention rescind breakthrough therapy designation certain genotype hepatitis c regimens related daclatasvir investigational bms therapies impact current submissionresubmission timetable new drug application daclatasvir combination antiviral agents treatment hepatitis c november company announced fda issued complete response letter crl regarding new drug application nda dcv combination agents treatment hepatitis c virus hcv initial dcv nda submitted fda focused use combination asv given withdrawal asv bms october fda requesting additional data dcv combination antiviral agents treatment hcv bms discussions fda scope data november company announced results unity trial program investigating week regimen alloral dcvtrio regimen fixed dose combination dcv asv bcv dcvtrio broad range patients genotype hcv primary endpoint studies percentage patients achieved cure defined hcv rnalloq tdtnd posttreatment week treatmentnave treatmentexperienced patients unity study evaluated cirrhotic patients week regimen dcvtrio showed sustained virologic response weeks treatment svr among treatmentnave treatmentexperienced cirrhotic patients ribavirin rbv treatmentnave treatmentexperienced cirrhotic patients without rbv november company announced results landmark ally trial investigating ribavirinfree week regimen dcv combination sofosbuvir sof genotype hcv patients population emerged one difficult treat results study showed sustained virologic response weeks treatment svr treatmentnave treatmentexperienced patients sof product gilead sciences inc gilead october company announced pursue fda approval dual regimen dcv asv treatment hcv genotype b patients us therefore withdrawn nda asunaprevir company continue pursue fda approval dcv currently investigated globally multiple treatment regimens hcv patients high unmet needs august company announced european commission ec approved daklinza use combination medicinal products across genotypes treatment chronic hcv infection adults daklinza used combination sof alloral interferonfree regimen provided cure rates clinical trials including patients advanced liver disease genotype previously failed treatment protease inhibitors daklinza first nsa complex inhibitor approved eu available use combination medicinal products providing shorter treatment duration weeks compared weeks treatment interferon ribavirinbased regimens july company announced japanese ministry health labor welfare approved daklinza sunvepra new hcv treatment lead cure many patients japan currently treatment options daklinza sunvepra dual regimen japans first alloral interferon ribavirinfree treatment regimen patients genotype chronic hcv infection including compensated cirrhosis indications daklinza sunvepra japan patients ineligible intolerant interferonbased therapy patients failed respond interferonbased therapy elotuzumab humanized monoclonal antibody investigated anticancer treatment elotuzumab part alliance abbvie inc abbvie may company abbvie announced fda granted elotuzumab breakthrough therapy designation use combination lenalidomide dexamethasone treatment multiple myeloma patients received one prior therapies designation based findings randomized phase ii openlabel study evaluated two dose levels elotuzumab combination lenalidomide lowdose dexamethasone previouslytreated patients including mgkg dose studied phase iii trials reyataz atazanavir sulfate franchise protease inhibitor treatment human immunodeficiency virus hiv includes reyataz also included combination therapy evotaz atazanavir mg cobicistat mg evotaz part alliance gilead january company announced fda approved evotaz tablets treatment hiv infection adults oncedaily single tablet two drug regimen combining reyataz tybost sustiva efavirenz franchise nonnucleoside reverse transcriptase inhibitor treatment hiv includes sustiva antiretroviral drug bulk efavirenz also included combination therapy atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg product sold joint venture gilead october company announced successfully resolved outstanding us patent litigation relating efavirenz active ingredient contained sustiva atripla loss exclusivity us efavirenz expected occur december yervoy ipilimumab monoclonal antibody treatment patients unresectable metastatic melanoma june company announced results phase iii randomized double blind study demonstrating yervoy mgkg significantly improved recurrencefree survival rfs length time recurrence death versus placebo patients stage melanoma high risk recurrence following complete surgical resection adjuvant setting reduction risk recurrence death observed three years estimated patients treated yervoy free disease recurrence compared estimated patients placebo median rfs months yervoy versus months placebo median followup years orencia abatacept fusion protein indicated adult patients moderate severe active rheumatoid arthritis ra also indicated reducing signs symptoms certain pediatric patients moderately severely active polyarticular juvenile idiopathic arthritis november company announced results several new subanalyses phase iiib avert assessing early rheumatoid arthritis treatment trial investigated use orencia plus methotrexate mtx biologic mtxnave citrullinated protein ccppositive early moderate severe ra patients firstline therapy orencia combination mtx resulted patients early ra achieving significantly higher rates stringent measures remission including percent patients achieving booleandefined remission percent patients achieving cdai sdai defined remission months versus patients mtx alone percent percent percent respectively p three measures june company announced first release new data phase iiib avert trial showing orencia combination mtx achieved significantly higher rates dasdefined remission months treatment standard care agent mtx biologic mtxnave patients early active ra eliquis apixaban oral factor xa inhibitor targeted stroke prevention nonvalvular atrial fibrillation nvaf prevention treatment venous thromboembolic vte disorders eliquis part alliance pfizer november company pfizer portola pharmaceuticals announced results first part phase annexaa andexanet alfa novel antidote anticoagulant effects fxa inhibitors apixaban studies andexanet alfa produced rapid nearly complete reversal approximately percent p value anticoagulant effect eliquis healthy volunteers ages august company pfizer announced results prespecified secondary analysis eliquis phase amplifyext trial apixaban initial management pulmonary embolism deep vein thrombosis firstline therapyextended treatment analysis evaluated clinical demographic predictors allcause hospitalization patients vte includes treatment deep vein thrombosis dvt pulmonary embolism pe results analysis demonstrated month extended treatment vte eliquis significantly reduced risk hospitalization versus placebo august company pfizer announced fda approved supplemental new drug application snda eliquis treatment dvt pe reduction risk recurrent dvt pe following initial therapy july company pfizer announced ec approved eliquis treatment dvt pe adults july company pfizer announced first patient enrolled phase iv clinical trial called emanate assessing effectiveness safety eliquis patients nvaf undergoing cardioversion march company pfizer announced results prespecified subanalysis phase iii aristotle trial assessing effect blood pressure control outcomes study showed results stroke risk reduction eliquis versus warfarin consistent overall aristotle study results demonstrating eliquis reduced stroke systemic embolism caused fewer major bleeding events reduced allcause mortality compared warfarin regardless blood pressure control results also showed poor blood pressure control associated substantially higher risk stroke systemic embolism independent eliquis warfarin treatment march company pfizer announced fda approved snda eliquis prophylaxis deep vein thrombosis may lead pe patients undergone hip knee replacement surgery february company pfizer announced results prespecified subanalysis phase iii aristotle trial relation patient age aristotle designed evaluate efficacy safety eliquis compared warfarin reducing risk stroke systemic embolism patients nvaf subanalysis found consistent results across age groups reducing risk stroke systemic embolism reducing risk allcause death fewer bleeding events eliquis versus warfarin owing higher risk older age age older absolute benefit patients nvaf greater eliquis older population results operations total revenues composition changes revenues follows year ended december vs vs total revenues analysis change analysis change total foreign total foreign dollars millions change volume price exchange change volume price exchange united states europe rest world othera na na na na na na total revenues include royalties alliancerelated revenues products sold regional commercial organizations change excess single country outside us contributed total revenues period presented general business seasonal change us revenues attributed volume resulted diabetes business divestiture february partially offset increased demand eliquis yervoy sprycel change us revenues attributed volume resulted exclusivity loss plavix may avaproavalide march partially offset increased demand sprycel yervoy amylinrelated diabetes product revenues following completion acquisition august change us revenues attributed price resulted higher average net selling prices abilify aripiprazole key products change us revenues attributed price resulted reduction share abilify revenues impact mostly offset higher average net selling prices abilify key products see key products discussion total revenues key product change europe revenues attributed volume resulted expiration eu commercialization rights abilify june diabetes business divestiture february loss exclusivity sustiva november partially offset increased demand eliquis yervoy orencia launch daklinza certain eu countries change europe revenues attributed volume resulted increased demand key products particularly yervoy sprycel orencia amylinrelated product revenues following transition nonus operations second quarter partially offset restructured sanofi agreement see item financial statementsnote alliances discussion revenues periods continued negatively impacted fiscal challenges many european countries healthcare payers including government agencies reduced expected continue reduce healthcare costs actions directly indirectly impose additional price reductions measures include mandatory discounts rebates restrictive measures change europe revenues attributed price also resulted reduction atripla revenue sharing average net selling prices change rest world revenues attributed volume resulted increased demand key products particularly eliquis yervoy sprycel launch daklinza sunvepra japan partially offset diabetes business divestiture change rest world revenues attributed volume resulted growth key products partially offset restructured sanofi agreement generic competition mature brands periods impacted unfavorable foreign exchange primarily japan revenues increased periods due higher royalties mature brand overthecounter product alliances diabetes product supply sales certain alliance revenues expected decline approximately million continue decline upon expiration related royalty alliance agreements item financial statementsnote alliances discussion alliances recognize revenue net grosstonet adjustments described critical accounting policies share certain abilify atripla revenues reflected net grosstonet adjustments alliance revenues although presented grosstonet adjustment tables share abilify atripla grosstonet adjustments approximately billion billion billion changes grossto net adjustments impacted additional rebates discounts required us healthcare reform reduction share abilify revenues activities ending reserve balances significant category grosstonet adjustments follows managed healthcare chargebacks rebates related government cash contract medicaid sales dollars millions programs discounts discounts rebates returns adjustments total balance january provision related sale made current period prior period returns payments assetsrelated liabilities heldforsale impact foreign currency translation balance december provision related sale made current period prior period returns payments impact foreign currency translation balance december reconciliation gross product sales net product sales significant category grosstonet adjustments follows year ended december dollars millions gross product sales grosstonet adjustments chargebacks related government programs cash discounts managed healthcare rebates contract discounts medicaid rebates sales returns adjustments total grosstonet adjustments net product sales grosstonet adjustment rates primarily function changes revenue mix contractual legislative discounts rebates grosstonet adjustments increased decreased due chargebacks related government programs cash discounts decreased result lower plavix sales following loss exclusivity managed healthcare rebates contract discounts decreased following diabetes business divestiture february partially offset higher eliquis sales managed healthcare rebates contract discounts increased primarily due higher amylinrelated sales medicaid rebates increased due incremental discounts price increases taken excess inflation higher program participation rates higher provision reversals related sales made prior periods medicaid rebates decreased due lower plavix sales higher provision reversals related sales made prior periods sales returns decreased due additional reserves established following plavix avaproavalide loss exclusivity us sales return reserves plavix avaproavalide million million december respectively determined considering several factors including estimated inventory levels distribution channels accordance company policy products eligible returned six months prior twelve months product expiration adjustments might required future resulting actual returns expected occur adjustments increased primarily due higher government rebates nonus markets product revenues change attributable year ended december change foreign exchange dollars millions vs vs vs vs virology baraclude entecavir us nonus hepatitis c franchise daclatasvir asunaprevir na na na na nonus na na na na reyataz atazanavir sulfate us nonus sustiva efavirenz franchise us nonus oncology erbitux cetuximab na us nonus na opdivo nivolumab na na na na us na na nonus na na na na sprycel dasatinib us nonus yervoy ipilimumab us nonus neuroscience abilify aripiprazole us nonus immunoscience orencia abatacept us nonus cardiovascular eliquis apixaban na na us na nonus na na diabetes alliance us nonus mature products us nonus change excess baraclude oral antiviral agent treatment chronic hepatitis b us revenues decreased due launch generic entecavir teva pharmaceutical industries ltd september us revenues increased due higher average net selling prices demand international revenues increased due higher demand hepatitis c franchise daklinza nsa replication complex inhibitor sunvepra ns protease inhibitor daklinza launched germany august certain eu countries september daklinza sunvepra dual regimen launched japan september reyataz protease inhibitor treatment hiv us revenues decreased periods due lower demand resulting competitors ' products international revenues decreased due timing government purchases certain countries lower demand resulting competitors ' products international revenues increased due higher demand timing government purchases certain countries periods impacted unfavorable foreign exchange sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv includes sustiva antiretroviral drug bulk efavirenz also included combination therapy atripla product sold alliance gilead us revenues increased periods due higher average net selling prices partially offset lower demand international revenues decreased due sustiva 's loss exclusivity europe november negatively impacted demand average net selling prices atripla revenue sharing erbitux monoclonal antibody designed exclusively target block epidermal growth factor receptor expressed surface certain cancer cells multiple tumor types well normal cells currently indicated use treatment patients certain types metastatic colorectal cancer squamous cell carcinoma head neck erbitux part alliance lilly us revenues remained flat periods opdivo fully human monoclonal antibody binds pd nkt cells investigated anticancer treatment opdivo part alliance ono opdivo launched us december japan september treatment unresectable metastatic melanoma sprycel oral inhibitor multiple tyrosine kinases indicated firstline treatment adults philadelphia chromosomepositive chronic myeloid leukemia chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib meslylate sprycel part alliance otsuka pharmaceutical co ltd otsuka us revenues increased periods primarily due higher demand international revenues increased periods primarily due higher demand partially offset unfavorable foreign exchange yervoy monoclonal antibody treatment patients unresectable metastatic melanoma us revenues increased periods due higher demand us revenues also favorably impacted recognition million revenues previously deferred international revenues increased periods due higher demand abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder part alliance otsuka us revenues increased primarily due higher average net selling prices partially offset reduction share abilify revenues us revenues decreased due reduction contractual share revenues partially offset higher average net selling prices us commercialization rights abilify expire april upon expected loss product exclusivity result significant decline abilify revenues international revenues decreased primarily due expiration eu commercialization rights june otsuka becoming principal end customer sales certain markets international revenues increased primarily due higher demand orencia fusion protein indicated adult patients moderate severe active ra also indicated reducing signs symptoms certain pediatric patients moderately severely active polyarticular juvenile idiopathic arthritis us revenues increased periods primarily due higher average net selling prices higher demand subcutaneous formulation international revenues increased periods primarily due higher demand subcutaneous formulation partially offset unfavorable foreign exchange eliquis oral factor xa inhibitor targeted stroke prevention nonvalvular atrial fibrillation prevention treatment vte disorders eliquis part alliance pfizer us international revenues continued increase following launches major markets reduction risk stroke systemic embolism patients nvaf treatment vte us diabetes alliance includes bydureon byetta farxiga onglyzakombiglyze myalept symlin part alliance astrazeneca revenues decreased due diabetes business divestiture february revenues increased due amylin acquisition august higher demand average net selling prices onglyzakombiglyze see item financial statementsnote alliances discussion mature products includes products including lost exclusivity major markets overthecounter brands royalty related revenue us revenues decreased periods due continued generic erosion certain products including plavix avaproavalide lost exclusivity resulting lower revenue billion international revenues remained relatively flat due continued generic erosion products offset higher revenues attributed certain alliances international revenues impacted changes attributed restructured sanofi agreement avaproavalide plavix see item financial statementsnote alliances discussion revenues expected significantly decline due reduction approximately million related expiration certain royalty alliance agreements well continued decline mature products estimated enduser demand pursuant us securities exchange commission sec consent order described sec consent order monitor level inventory hand us wholesaler distribution channel outside us direct customer distribution channel obligated disclose products levels inventory excess one month hand expected demand subject de minimis exception estimated levels inventory distribution channel excess one month hand following products material results operations dates indicated reyataz months inventory hand internationally september compared months inventory hand june level inventory exceeds one month hand primarily due government purchasing patterns brazil efferalgan analgesic product sold principally europe months inventory hand internationally september june level inventory hand primarily due ordering patterns pharmacists france us generally determine months hand estimates using inventory levels product hand amount outmovement provided three largest wholesalers account approximately total gross sales us products factors may influence estimates include generic competition seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data may impacted recordkeeping processes businesses outside us significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely direct customer product level inventory ultimate patientconsumer demand outmovement data exist otherwise available developed variety methodologies estimate data including using factors historical sales made direct customers thirdparty market research data related prescription trends enduser demand accordingly rely variety methods estimate direct customer product level inventory calculate months hand factors may affect estimates include generic competition seasonality products direct customer purchases light price increases new product launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations information required estimate months hand direct customer distribution channel nonus business year ended december available prior filing annual report disclose product levels inventory excess one month hand expected demand subject de minimis exception next quarterly report form q expenses change dollar millions vs vs cost products sold marketing selling administrative advertising product promotion research development impairment charge bms intangible asset incomeexpense total expenses change excess cost products sold cost products sold include material costs internal labor overhead owned manufacturing sites thirdparty processing costs supply chain costs settlement foreign currency forward contracts used hedge forecasted intercompany inventory purchase transactions essentially costs managed global manufacturing supply organization cost products also includes royalties profit sharing attributed licensed products alliances amortization acquired developed technology costs business combinations milestone payments occur regulatory approval cost products sold vary periods result product mix particularly resulting royalties profit sharing expenses connection alliances price inflation costs attributed rationalization manufacturing sites resulting accelerated depreciation impairment charges stranded costs addition changes foreign currency may also provide volatility certain costs denominated foreign currencies cost products sold percentage total revenues cost products sold decreased primarily due diabetes business divestiture billion partially offset higher eliquis profit sharing pfizer accelerated depreciation certain manufacturing facilities cost products sold remained relatively flat higher profit sharing expenses higher net amortization costs following amylin acquisition offset lower royalties following loss exclusivity plavix avaproavalide lower impairment charges impairment charges million recognized including million related continued competitive pricing pressures reduction undiscounted projected cash flows amount less carrying value developed technology intangible asset remaining million impairment charge related abandonment manufacturing facility resulting outsourcing manufacturing process marketing selling administrative marketing selling administrative expenses include salary benefit costs thirdparty professional marketing fees outsourcing fees shipping handling costs expenses attributed product manufacturing costs research development expenses expenses managed regional commercialization organizations global corporate organizations finance legal information technology human resources certain expenses shared alliance partners based upon contractual agreements marketing selling administrative expenses remained relatively flat increased salesrelated activities supporting eliquis yervoy opdivo hepatitis c franchise higher variable employee compensation additional branded prescription drug fee offset lower expenses following diabetes business divestiture million july irs issued final rules regulations branded prescription drug fee annual nontaxdeductible fee payable federal government affordable care act based allocation companys market share branded prescription drugs sold certain government programs prior year final rules accelerated bms 's industry participants ' expense recognition criteria fee obligation year fee paid year market share used allocate fee determined result additional year expense recognized third quarter including million marketing selling administrative expenses million expense final rules regulations change amount timing annual fees paid marketing selling administrative expenses decreased due accelerated vesting amylin stock options restricted stock units million lower branded prescription drug fee reduction sales related activities certain products coincide respective lifecycles partially offset higher spending support launch new key products additional spending following amylin acquisition advertising product promotion advertising product promotion expenses include media sample direct consumer programs advertising product promotion expenses decreased following diabetes business divestiture advertising product promotion expenses increased due newly launched products research development research development expenses include salary benefit costs thirdparty grants fees paid clinical research organizations supplies facility costs research development expenses also include costs discovery research preclinical development early lateclinical development drug formulation well clinical trials medical support marketed products proportionate allocations enterprisewide costs facilities information technology employee stock compensation costs appropriate costs upfront licensing fees related payments upon achievement regulatory contractual milestones also included certain expenses shared alliance partners based upon contractual agreements expenses attributed development activities managed global research development organization approximately billion billion billion remainder attributed preclinical research activities expenses vary periods number reasons including timing upfront milestone licensing payments research development expenses increased due million iprd impairment charges including million peginterferon lambda higher variable employee compensation clinical development costs million charge acquisition ipierian upfront contingent milestone payments million see item financial statements note acquisitions note goodwill intangible assets information research development expenses decreased due prior year charges including million iprd impairment charges million accelerated vesting amylin stock options restricted stock units million upfront milestone licensing payments partially offset additional costs following amylin acquisition higher clinical grant spending impairment charge bms intangible asset billion impairment charge recognized development bms formerly inx compound acquired part acquisition inhibitex treat hcv discontinued interest patient safety see item financial statements note goodwill intangible assets information intangible assets highly vulnerable impairment charges particularly newly acquired assets recently launched products iprd assets initially measured fair value therefore reduction expectations used valuations could potentially lead impairment see critical accounting policies discussion incomeexpense year ended december dollars millions interest expense investment income provision restructuring litigation chargesrecoveries equity net income affiliates outlicensed intangible asset impairment gain sale product lines businesses assets alliance licensing income pension curtailments settlements special termination benefits incomeexpense provision restructuring primarily attributable employee termination benefits resulting workforce reductions manufacturing selling administrative research development personnel across geographic regions additional charges approximately million related specialty care transformation initiatives expected see item financial statementsnote restructuring discussion litigation chargesrecoveries included million share apotex damages award concerning plavix equity net income affiliates primarily related international partnership sanofi europe asia decreased periods result restructuring sanofi agreement continues negatively impacted generic competition plavix europe asia outlicensed intangible asset impairment charges related certain assets acquired medarex zymogenetics inc acquisitions resulted unfavorable clinical trial results andor abandonment programs gain sale product lines businesses assets resulted primarily diabetes business divestiture see item financial statementsnote alliances details alliance licensing income includes royalties transitional service fees amortization deferred income attributed development agreement resulting diabetes business divestiture decrease us plavix sales resulted lower development royalties owed sanofi royalties received sanofi except europe asia presented revenues beginning result restructured sanofi agreement see item financial statementsnote alliances discussion pension settlement charge million recognized following purchase group annuity contract prudential december additional pension settlement charges also recognized determining annual lump sum payments would exceed annual interest service costs certain pension plans including primary us pension plan charges include acceleration portion unrecognized actuarial losses similar charges may occur future see item financial statementsnote pension postretirement postemployment liabilities details income taxes dollars millions earnings income taxes provision forbenefit income taxes effective taxbenefit rate historically effective income tax rate lower us statutory rate due decision indefinitely reinvest earnings certain manufacturing operations ireland puerto rico favorable tax rates ireland puerto rico grants scheduled expire prior increase effective tax rate resulted unfavorable earnings mix high low tax jurisdictions retroactive reinstatement rd credit legislation additional tax reserves transfer pricing matters partially offset higher tax benefits attributed specified items minimal income taxes attributed diabetes business divestiture gain capital loss deduction sale amylin shares tax basis differences resulting primarily allocated goodwill amylin deferred taxes tax benefits attributed research development charge resulting acquisition ipierian change effective tax rate resulted million tax benefit attributed capital loss deduction resulting tax insolvency inhibitex impact deduction reduced effective tax rate percentage points changes resulting lower discrete tax benefits attributed intangible asset impairment charges million impairment charge bms higher charges contingent tax matters offset favorable earnings mix higher us plavix sales retroactive reinstatement rd credit legislation see item financial statementsnote income taxes details noncontrolling interest see item financial statementsnote alliances discussion plavix avaproavalide partnerships sanofi territory covering americas decrease noncontrolling interest resulted exclusivity loss us plavix may avaproavalide march summary noncontrolling interest follows year ended december dollars millions sanofi partnerships noncontrolling interestpretax income taxes net earnings attributable noncontrolling interest nongaap financial measures nongaap financial measures including nongaap earnings related eps information adjusted exclude certain costs expenses gains losses specified items due significant andor unusual nature evaluated individual basis similar charges gains items recognized prior periods reasonably possible could reoccur future periods nongaap information intended portray results baseline performance include discovery development licensing manufacturing marketing distribution sale pharmaceutical products global basis enhance investors overall understanding past financial performance prospects future example nongaap earnings eps information indication baseline performance items considered us reflective ongoing results addition information among primary indicators use basis evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods information intended considered isolation substitute net earnings diluted eps prepared accordance gaap specified items follows year ended december dollars millions accelerated depreciation asset impairment shutdown costs amortization acquired amylin intangible assets amortization amylin alliance proceeds amortization amylin inventory adjustment cost products sold stock compensation accelerated vesting amylin awards additional year branded prescription drug fee process standardization implementation costs marketing selling administrative stock compensation accelerated vesting amylin awards upfront milestone licensing payments iprd impairment research development impairment charge bms intangible asset provision restructuring gain sale product lines businesses assets pension curtailments settlements special termination benefits acquisition alliance related itemsa litigation chargesrecoveries loss debt redemption outlicensed intangible asset impairment upfront milestone licensing receipts incomeexpense increase pretax income income tax items specified tax chargebenefitbc income taxes increase net earnings includes million additional year branded prescription drug fee third quarter b specified tax charge relates transfer pricing matters c specified tax benefit relates capital loss deduction reconciliations gaap nongaap follows year ended december dollars millions except per share data net earnings attributable bms gaap earnings attributable unvested restricted shares net earnings attributable bms used diluted eps calculation gaap net earnings attributable bms gaap less specified items net earnings attributable bms nongaap earnings attributable unvested restricted shares net earnings attributable bms used diluted eps calculation nongaap average common shares outstanding diluted diluted eps attributable bms gaap diluted eps attributable specified items diluted eps attributable bms nongaap financial position liquidity capital resources net cashdebt position follows dollars millions cash cash equivalents marketable securities current marketable securities noncurrent total cash cash equivalents marketable securities shortterm borrowings longterm debt net cashdebt position cash cash equivalents marketable securities held us approximately billion december remaining billion held primarily lowtax jurisdictions attributable earnings expected indefinitely reinvested offshore cash repatriations subject restrictions certain jurisdictions may subject withholding additional us income taxes believe existing cash cash equivalents marketable securities together cash generated operations sufficient satisfy normal cash requirements least next years including dividends capital expenditures milestone payments working capital dividends billion billion dividend decisions made quarterly basis board directors capital expenditures approximately million past three years expected increase approximately billion higher spending expected result expanding biologics manufacturing capabilities facilityrelated activities example planning construct new largescale biologics manufacturing facility ireland produce multiple therapies growing biologics portfolio completed february sold astrazeneca substantially diabetes business comprising alliance resulting billion cash flow including royalties see item financial statementsnote alliances discussion also redeemed notes due entirety outstanding principal amount notes million management periodically evaluates potential opportunities repurchase certain debt securities terminate certain interest rate swap contracts prior maturity commercial paper borrowings outstanding december marketable securities portfolio subject changes fair value result interest rate fluctuations market factors may impact results operations investment policy places limits investments amount time maturity investments institution policy also requires investments entered corporate financial institutions meet high credit quality standards see item financial statements note financial instruments fair value measurements two separate billion fiveyear revolving credit facilities maintained syndicate lenders facilities provide customary terms conditions financial covenants extendable anniversary date consent lenders borrowings outstanding either revolving credit facility december additional regulations us could passed future could reduce results operations operating cash flow liquidity financial flexibility also continue monitor potential impact economic conditions certain european countries related impact prescription trends pricing discounts creditworthiness customers ability collect outstanding receivables direct customers currently believe economic conditions eu material impact liquidity cash flow financial flexibility exposure certain european governmentbacked entities higher risk default governmentbacked entities monitored economic factors including credit ratings creditdefault swap rates debttogross domestic product ratios addition entity specific factors exposure reduced factoring certain receivables including receivables italy portugal spain million million million factoring receivables japan million million million factoring agreements allow recourse event uncollectibility retain interest underlying assets sold continue manage operating cash flows focusing working capital items directly affected changes sales volume receivables inventories accounts payable dollars millions december december net trade receivables inventories accounts payable total credit ratings moodys investors service longterm shortterm credit ratings prime respectively longterm credit outlook negative standard poors longterm shortterm credit ratings respectively longterm credit outlook stable fitch 's longterm shortterm credit ratings f respectively revised longterm credit outlook negative stable december credit ratings considered investment grade longterm ratings reflect agencies ' opinion low default risk somewhat susceptible adverse effects changes circumstances economic conditions shortterm ratings reflect agencies ' opinion good extremely strong capacity timely repayment cash flows following discussion cash flow activities dollars millions cash flow provided byused operating activities investing activities financing activities operating activities cash flow operating activities represents cash receipts cash disbursements activities investing activities financing activities operating cash flow derived adjusting net earnings noncontrolling interest noncash operating items gains losses attributed investing financing activities changes operating assets liabilities resulting timing differences receipts payments cash transactions recognized results operations result changes cash operating activities reflect timing cash collections customers alliance partners payments suppliers alliance partners employees pension contributions tax payments ordinary course business million decrease cash provided operating activities primarily attributable lower upfront contingent alliance proceeds approximately million reckitt alliance proceeds million additional net working capital requirements million partially offset timing cash collections payments ordinary course business including among items lower pension contributions restructuring annual bonus payments billion decrease cash provided operating activities primarily attributable lower upfront contingent alliance proceeds approximately billion amylin alliance proceeds billion lower operating cash flows attributed plavix avaproavalide revenue reductions following loss exclusivity approximately million investing activities cash requirements investing activities include cash used business acquisitions manufacturing facilityrelated capital expenditures purchase marketable securities maturities greater days reduced proceeds business divestitures sale maturity marketable securities billion decrease cash used investing activities primarily attributable proceeds billion allocated diabetes business divestiture partially offset higher net purchases marketable securities approximately billion cash used acquire ipierian million billion decrease cash used investing activities primarily attributable cash used acquire amylin billion inhibitex billion partially offset higher net proceeds sales purchases maturities marketable securities approximately billion financing activities cash requirements financing activities include cash used pay dividends repurchase common stock repay longterm debt borrowings reduced proceeds exercise stock options issuance longterm debt borrowings billion increase cash used financing activities primarily attributable lower net borrowings longterm debt transactions billion million repayments million net borrowings lower proceeds stock option exercises million million including excess tax benefits partially offset lower cash used repurchase common stock none million billion decrease cash used financing activities primarily attributable lower cash used repurchase common stock billion million billion higher net borrowings longterm debt transactions billion million net borrowings million net repayments including debt assumed amylin acquisition higher proceeds stock option exercises million million including excess tax benefits contractual obligations payments due period contractual obligations december follows obligations expiring period dollars millions total later years shortterm borrowings longterm debt interest longterm debta operating leases purchase obligations uncertain tax positionsb longterm liabilities total includes estimated future interest payments periodic cash settlements derivatives b includes shortterm uncertain tax benefits uncertainties regarding timing resolution addition committed aggregated billion potential future research development milestone payments third parties licensing development programs including earlystage milestones million milestones achieved phase iii clinical trials latestage milestones billion milestones achieved post phase iii clinical trials payments generally due payable upon achievement certain developmental regulatory milestones specific timing predicted agreements also provide salesbased milestones aggregating billion would obligated pay alliance partners upon achievement certain sales levels addition royalties also certain manufacturing development commercialization obligations connection alliance arrangements practicable estimate amount obligations see item financial statementsnote alliances information regarding alliances discussion contractual obligations see item financial statementsnote income taxes note financial instruments fair value measurements note pension postretirement postemployment liabilities note leases sec consent order previously disclosed august entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit quarterly report form q period ended september terms consent agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring budget process gives appropriate weight inputs come bottom top top bottom adequately documenting process established companywide policy limit sales direct customers purpose complying consent policy includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basis maintain inventory management agreements imas us pharmaceutical wholesalers account nearly gross us revenues current terms imas wholesaler customers provide us weekly information respect months hand productlevel inventories amount outmovement products three largest wholesalers currently account approximately gross us revenues inventory information received wholesalers together internal information used estimate months hand product level inventories wholesalers estimate months hand product inventory levels us businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers contrast nonus business significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly rely variety methods estimate months hand product level inventories business units believe abovedescribed procedures provide reasonable basis ensure compliance consent recently issued accounting standards recently issued accounting standards see item financial statementsnote accounting policiesrecently issued accounting standards critical accounting policies preparation financial statements requires use estimates assumptions affect reported amounts assets liabilities reported amounts revenue expenses critical accounting policies significantly impact financial condition results operations require difficult subjective complex judgments often result need make estimates effect matters inherently uncertain uncertainty actual results may vary estimates accounting policies discussed audit committee board directors revenue recognition accounting policy revenue recognition substantial impact reported results relies certain estimates revenue recognized persuasive evidence arrangement exists sales price fixed determinable collectability reasonably assured title substantially risks rewards ownership transferred generally upon shipment except certain eu markets occur delivery products customer deferred approximately million products sold early access program eu portion amount recognized revenue subject final price negotiations local government expected concluded revenue also reduced grosstonet sales adjustments discussed involve significant estimates judgment considering legal interpretations applicable laws regulations historical experience payer channel mix eg medicare medicaid current contract prices applicable programs unbilled claims processing time lags inventory levels distribution channel estimates assessed period adjusted required revised information actual experience addition see total revenues discussion analysis significant category grosstonet sales adjustments alliance arrangements involving delivery one element undelivered element evaluated whether qualifies separate unit accounting consideration fixed determinable allocated undelivered element recognized related goods services delivered limited consideration contingent upon future deliverables consideration associated contingent milestones royalties allocated among underlying elements amounts determined payable bms grosstonet adjustments following categories grosstonet adjustments involve significant estimates judgments information obtained external sources chargebacks related government programs us business participates programs government entities significant us department defense us department veterans affairs parties including covered entities b drug pricing program whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower program price wholesalers charge us difference acquisition cost lower program price accounts receivable reduced estimated amount unprocessed chargeback claims attributable sale typically within two four week time lag cash discounts us certain countries cash discounts offered incentive prompt payment generally approximating sales price accounts receivable reduced estimated amount unprocessed cash discounts typically within one month time lag managed healthcare rebates contract discounts rebates discounts offered managed healthcare organizations us managing prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit addition commercial plans well contract counterparties hospitals group purchasing organizations globally rebates also required us department defense tricare retail pharmacy refund program estimated amount unpaid unbilled rebates discounts presented liability million reversal estimated amount medicare part coverage gap discounts occurred receipt actual invoices medicaid rebates us business participates state government medicaid programs qualifying federal state government programs requiring discounts rebates participating state local government entities discounts rebates provided programs included medicaid rebate accrual medicaid rebates also extended drugs used managed medicaid plans estimated amount unpaid unbilled rebates presented liability estimated medicaid rebates attributable prior period revenues reduced million million million sales returns products typically eligible returned six months prior twelve months product expiration accordance policy estimated returns established products determined considering historical experience factors including levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products lower demand following loss exclusivity estimated amount product returns presented liability reserves established plavix avaproavalide following loss exclusivity remaining reserves million million december respectively considering relevant factors well estimated future retail wholesale inventory work would occur loss exclusivity estimated returns new products determined considering historical sales return experience similar products within product line similar therapeutic category defer recognition revenue right return expires sufficient historical experience estimate sales returns developed limited circumstances typically occurs new product extension existing line product historical experience products similar therapeutic category lacking estimated levels inventory distribution channel projected demand also considered estimating sales returns new products use information external sources information external sources used estimate grosstonet adjustments estimate inventory wholesalers based projected prescription demandbased sales products historical inventory experience well analysis thirdparty information including written oral information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals also continued practice combining retail mail prescription volume retailequivalent basis use methodology internal demand forecasts also use information external sources identify prescription trends patient demand average selling prices estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date receive thirdparty information retirement benefits accounting pension postretirement benefit plans requires actuarial valuations based significant assumptions discount rates expected longterm rates return plan assets consultation actuaries significant assumptions others salary growth retirement turnover healthcare trends mortality rates evaluated selected based expectations actual experience remeasurement date pension expense could vary within range outcomes material effect reported earnings projected benefit obligations future cash funding actual results given year may differ estimated economic factors yield high quality corporate bonds coincides cash flows plans estimated payouts used determining discount rate citigroup pension discount curve used us plans us plans pension expense determined using weightedaverage discount rate present value benefit obligations december us pension plans determined using discount rate discount rate used determining us plans pension expense reduced additional expense would increase approximately million assumed discount rate used determining us pension plans projected benefit obligation december reduced additional projected benefit obligation would increase approximately billion new mortality tables rp mortality improvement scales mp issued society actuaries reflecting longer life expectancies previous tables new tables used measure us pension postretirement obligations beginning september resulting increase obligations approximately million revised mortality rates expected materially impact pension expense future periods expected longterm rate return plan assets estimated considering expected returns individual asset classes input external advisors also consider longterm historical returns including actual performance compared benchmarks similar investments us plans pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increase million detailed discussion retirement benefits see item financial statementsnote pension postretirement postemployment liabilities business combinations divestitures goodwill intangible assets acquired business combinations licensing transactions billion representing total assets december accounting transactions business combinations divestitures significantly different asset acquisitions divestitures example acquired iprd capitalized business combinations expensed asset acquisitions fair value contingent consideration goodwill recognized business combination transactions likewise portion reporting unit constitutes business divested goodwill associated business included carrying value business determining gain loss derecognition goodwill occur asset dispositions result important determine whether business asset group assets acquired divested business defined asc business combinations integrated set inputs processes capable generating outputs ability provide return investors owners typical inputs include longlived assets including intangible assets rights use longlived assets intellectual property ability obtain access required resources typical processes include strategic operational resource management processes typically documented evident organized workforce consider factors determining whether business acquired divested well stage development commercial products involved example evaluating acquisition ipierian concluded significant processes transferred us thus transaction accounted asset acquisition result million allocated lead investigational compound expensed capitalized addition contingent consideration potential regulatory approval milestones million salesbased royalties included purchase price similarly evaluating divestiture diabetes franchise astrazeneca concluded necessary inputs processes transferred consequently transaction accounted sale business resulted allocation million goodwill carrying value business determining gain sale business combination transactions assets acquired liabilities assumed recognized date acquisition respective fair values excess purchase price estimated fair values net assets acquired recognized goodwill fair value intangible assets including iprd typically determined using income method method starts forecast net cash flows risk adjusted estimated probabilities technical regulatory success iprd adjusted present value using appropriate discount rate reflects risk associated cash flow streams assets valued market participant view might different specific bms views valuation process complex requires significant input judgment using internal external sources although valuations required finalized within oneyear period must consider facts evidence available acquisition date complex judgmental matters applicable valuation process summarized unit accounting intangible assets valued single global assets rather multiple assets jurisdiction indication considering development stage expected levels incremental costs obtain additional approvals risks associated development amount timing benefits expected derived future expected patent lives various jurisdictions intention promote asset global brand estimated useful life asset life expected contribute meaningful cash flows determined considering pertinent matters associated asset including expected regulatory approval dates unapproved exclusivity periods legal regulatory contractual provisions well effects obsolescence demand competition economic factors including barriers entry probability technical regulatory success ptrs rate ptrs rates determined based upon industry averages considering respective programs development stage disease indication adjusted specific information data known acquisition date subsequent clinical results internal external data obtained could alter ptrs rate materially impact estimated fair value intangible asset subsequent periods leading impairment charges projections future revenues estimated considering many factors initial market opportunity pricing sales trajectories peak sales levels competitive environment product evolution future costs expenses estimated considering historical market trends market participant synergies timing level additional development costs obtain initial additional regulatory approvals maintain enhance product generally assume initial positive cash flows commence shortly receipt expected regulatory approvals typically may occur number years actual cash flows attributed project likely different assumed since projections subjected multiple factors including trial results regulatory matters could materially change ultimate commercial success asset well significantly alter costs develop respective asset commercially viable products tax rates expected future income tax effected using market participant tax rate recent valuations typically use us tax rate applicable state taxes considering jurisdiction intellectual property held location research manufacturing infrastructure also considered earnings repatriation would likely us tax consequences discount rate discount rates selected considering risks inherent future cash flows assessment assets life cycle competitive trends impacting asset including consideration technical legal regulatory economic barriers entry well expected changes standards practice indications addressed asset see item financial statementsnote acquisitions specific details values assigned assets acquired liabilities assumed acquisitions ipierian amylin inhibitex significant estimates utilized time valuations support fair values lead compounds within acquisitions include estimated phase year first discount useful life development projected positive dollars millions fair value rate utilized years acquisition date ptrs rate utilized cash flow commercialized products bydureon na na na byetta na na na symlin na na na iprd bms formerly inx na phase ii myalept na phase iii valuation processes also required certain multiple element arrangements include determination judgmental complex matters discussed example divestiture diabetes business astrazeneca required determination best estimated selling price several elements including business supply development agreements including appropriate markups estimated fair value manufacturing facility see item financial statementsnote alliances discussion impairment goodwill goodwill billion december goodwill tested least annually impairment enterprise level assessing qualitative factors performing quantitative analysis determining whether likely fair value exceeds carrying value examples qualitative factors assessed current year included share price financial performance compared budgets longterm financial plans macroeconomic industry market conditions well substantial excess fair value carrying value net assets annual impairment test performed prior year positive negative influences relevant factor assessed individually aggregate result concluded additional quantitative testing required discussion goodwill acquired inprocess research development intangible assets see item financial statementsnote accounting policiesgoodwill acquired inprocess research development intangible assets intangible assets including iprd intangible assets billion december including licenses million developed technology rights million capitalized software million iprd million intangible assets assessed impairment whenever current facts circumstances warrant review although iprd assessed least annually intangible assets highly vulnerable impairment charges particularly newly acquired assets recently launched products iprd assets initially measured fair value therefore reduction expectations used valuations could potentially lead impairment common potential risks leading impairment include competition earlier expected loss exclusivity pricing pressures adverse regulatory changes clinical trial results delay failure obtain regulatory approval additional development costs inability achieve expected synergies higher operating costs changes tax laws macroeconomic changes complexity estimating fair value intangible assets connection impairment test similar initial valuation considering high risk nature research development industrys success rate bringing developmental compounds market iprd impairment charges likely occur future periods recognized charges million including million charge peginterferon lambda phase iii development treatment hcv also recognized charges billion including billion charge resulting discontinued development bms projects previously acquired medarex inc inhibitex acquisitions resulting unfavorable clinical trial results additional development costs extended development periods decisions cease development iprd closely monitored assessed period impairment discussion iprd impairments see item financial statementsnote goodwill intangible assets addition iprd commercial assets also subject impairment example impairment charge million recognized related nonkey product prior acquisition continuing competitive pricing pressures operate dynamic market regulatory environment events occur causing expectations change quickly thus leading potential impairment charges property plant equipment property plant equipment tested impairment whenever current facts circumstances warrant review additionally longlived assets periodically reviewed determine change facts circumstances would result change estimated useful life asset possibly resulting acceleration depreciation circumstances exist estimate undiscounted future cash flows generated asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value expectations future cash flows subject change based upon near longterm production volumes margins generated asset well potential alternative future use accelerated depreciation related charges certain manufacturing facilities million million million contingencies normal course business subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability contractual claims tax matters recognize accruals contingencies probable liability incurred amount loss reasonably estimated estimates subject uncertainties difficult predict actual results could vary estimates discussions contingencies see item financial statementsnote accounting policiescontingencies note income taxes note legal proceedings contingencies income taxes valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecasts future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made deferred tax assets billion december net valuation allowances billion billion december net valuation allowances billion deferred tax assets related us federal net operating loss carryforward million us federal tax credit carryforward million recognized december net operating loss carryforward expires varying amounts beginning us federal tax credit carryforward expires varying amounts beginning realization carryforwards dependent generating sufficient domesticsourced taxable income prior expiration although assured believe likely deferred tax assets realized addition deferred tax asset related us federal state capital loss million recognized december carried back three years carried forward five years realization carryforward dependent upon generating sufficient capital gains prior expiration million valuation allowance established item december taxes provided undistributed earnings foreign subsidiaries expected reinvested indefinitely offshore prior mead johnson nutrition company mead johnson splitoff following transactions occurred internal spinoff mead johnson shares still owned us ii conversion mead johnson class b shares class shares iii conversion mead johnson company limited liability company transactions well splitoff mead johnson exchange offer qualify taxexempt transactions internal revenue code based upon private letter ruling received internal revenue service related conversion mead johnson class b shares class shares outside legal opinions certain assumptions representations covenants mead johnson relied upon regarding future conduct business matters could affect tax treatment exchange example current tax law generally creates presumption exchange would taxable us mead johnson shareholders engage transactions result greater change stock ownership four year period beginning two years exchange offer unless established exchange offer part plan series related transactions effect change ownership internal spinoff exchange offer determined qualify tax exempt transaction transaction could subject tax exchange taxable sale us market value addition negative basis excess loss account ela existed investment stock mead johnson prior transactions received opinion outside legal counsel effect likely eliminated ela part transactions taxable income respect ela tax law area complex possible even internal spinoff exchange offer tax exempt internal revenue code irs could assert additional taxable income period respect ela could exposed additional taxes occur based upon understanding internal revenue code opinion outside legal counsel tax reserve million established reducing gain disposal mead johnson included discontinued operations agreed certain tax related indemnities mead johnson set forth tax sharing agreement including certain taxes related business prior completion ipo created part restructuring facilitate ipo mead johnson also agreed indemnify us potential tax effects resulting breach certain representations discussed well certain transactions related acquisition mead johnsons stock assets liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known example additional reserves million established certain transfer pricing matters related periods discussions income taxes see item financial statementsnote accounting policiesincome taxes note income taxes special note regarding forwardlooking statements annual report including documents incorporated reference written oral statements make time time contain certain forwardlooking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things goals plans projections regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including internal external factors could delay divert change next several years included important factors cautionary statements included annual report particularly item risk factors believe could cause actual results differ materially forwardlooking statement although believe prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made undertake obligation release publicly revisions forwardlooking statements result new information future events otherwise item quantitative qualitative disclosures market risk exposed market risk resulting changes currency exchange rates interest rates certain derivative financial instruments used available costeffective basis hedge underlying economic exposure financial instruments including derivatives subject counterparty credit risk considered part overall fair value measurement derivative financial instruments used trading purposes foreign exchange risk significant amounts revenues earnings cash flow exposed changes foreign currency rates primary net foreign currency translation exposures euro japanese yen chinese renminbi canadian dollar south korean foreign currency forward contracts used manage risk primarily arises certain intercompany purchase transactions designated foreign currency cash flow hedges appropriate addition exposed foreign exchange transaction risk arising nonfunctional currency denominated assets liabilities earnings denominated nonus dollar currencies foreign currency forward contracts used offset exposures designated hedges estimate appreciation underlying currencies hedged levels us dollar variables held constant would decrease fair value foreign exchange forward contracts million december reducing earnings remaining life contracts also exposed translation risk nonus dollardenominated net assets nonus dollar borrowings used hedge foreign currency exposures net investment certain foreign affiliates designated hedges net investments effective portion foreign exchange gains losses hedges included foreign currency translation component accumulated comprehensive incomeloss net investment decreases equivalent value nonus debt borrowings change remeasurement basis debt would subject recognition income changes occur additional information see item financial statementsnote financial instruments fair value measurements interest rate risk fixedtofloating interest rate swap contracts used designated fairvalue hedges part interest rate risk management strategy contracts intended provide us appropriate balance fixed floating rate debt estimate increase basis points shortterm longterm interest rates would decrease fair value interest rate swap contracts million excluding effects counterparty credit risk reducing earnings remaining life contracts estimate increase basis points longterm interest rates would decrease fair value longterm debt million marketable securities subject changes fair value result interest rate fluctuations market factors policy invest institutions meet high credit quality standards estimate increase basis points interest rates general would decrease fair value debt security portfolio approximately million credit risk although material certain european governmentbacked entities higher risk default monitored economic factors including credit ratings creditdefault swap rates debttogross domestic product ratios entity specific factors historically exposure limited factoring receivables credit exposures europe may increase future due reductions factoring arrangements ongoing sovereign debt crisis credit exposure trade receivables greece portugal italy spain approximately million december approximately governmentbacked entities monitor investments counterparties objective minimizing concentrations credit risk investment policy establishes limits amount time maturity investments individual counterparty policy also requires investments entered corporate financial institutions meet high credit quality standards use derivative instruments exposes us credit risk fair value derivative instrument contract positive exposed credit risk counterparty fails perform fair value derivative instrument contract negative counterparty exposed credit risk fail perform obligation collateral required party whether derivatives asset liability position policy diversifying derivatives counterparties mitigate overall risk counterparty defaults additional information see item financial statementsnote financial instruments fair value measurements item financial statements supplementary data bristolmyers squibb company consolidated statements earnings dollars shares millions except per share data year ended december earnings net product sales alliance revenues total revenues cost products sold marketing selling administrative advertising product promotion research development impairment charge bms intangible asset incomeexpense total expenses earnings income taxes provision forbenefit income taxes net earnings net earnings attributable noncontrolling interest net earnings attributable bms earnings per common share basic diluted cash dividends declared per common share consolidated statements comprehensive income dollars millions year ended december comprehensive income net earnings comprehensive incomeloss net taxes reclassifications earnings derivatives qualifying cash flow hedges pension postretirement benefits availableforsale securities foreign currency translation total comprehensive incomeloss comprehensive income comprehensive income attributable noncontrolling interest comprehensive income attributable bms accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated balance sheets dollars millions except share per share data december assets current assets cash cash equivalents marketable securities receivables inventories deferred income taxes prepaid expenses assets heldforsale total current assets property plant equipment goodwill intangible assets deferred income taxes marketable securities assets total assets liabilities current liabilities shortterm borrowings accounts payable accrued expenses deferred income accrued rebates returns income taxes payable dividends payable liabilities related assets heldforsale total current liabilities pension postretirement postemployment liabilities deferred income income taxes payable liabilities longterm debt total liabilities commitments contingencies note equity bristolmyers squibb company shareholders equity preferred stock convertible series par value per share authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued capital excess par value stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million total bristolmyers squibb company shareholders ' equity noncontrolling interest total equity total liabilities equity accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated statements cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities net earnings attributable noncontrolling interest depreciation amortization net deferred income taxes stockbased compensation impairment charges pension settlements amortization proceeds amylin diabetes alliance gain sale businesses changes operating assets liabilities receivables inventories accounts payable deferred income income taxes payable net cash provided operating activities cash flows investing activities proceeds sale maturities marketable securities purchases marketable securities additions property plant equipment capitalized software business divestitures proceeds business acquisitions payments net cash provided byused investing activities cash flows financing activities shortterm debt borrowings net proceeds issuance longterm debt repayments longterm debt interest rate swap contract terminations issuances common stock repurchases common stock dividends net cash used financing activities effect exchange rates cash cash equivalents increasedecrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statements note accounting policies basis consolidation consolidated financial statements prepared conformity united states us generally accepted accounting principles gaap including accounts bristolmyers squibb company controlled majorityowned subsidiaries certain variable interest entities may referred bristol myers squibb bms company intercompany balances transactions eliminated material subsequent events evaluated disclosed report issuance date alliance license arrangements assessed determine whether terms provide economic control entity requiring consolidation entity entities controlled means majority voting interest referred variable interest entities consolidated bms power direct activities variable interest entity significantly impacts economic performance obligation absorb losses right receive benefits could potentially significant entity use estimates preparation financial statements requires use management estimates assumptions significant assumptions estimates determining fair value potential impairment intangible assets sales rebate return accruals legal contingencies income taxes estimated selling prices used multiple element arrangements pension postretirement benefits actual results may differ estimated results reclassifications certain prior period amounts reclassified conform current period presentation revenue recognition revenue recognized persuasive evidence arrangement exists sales price fixed determinable collectability reasonably assured title substantially risks rewards ownership transferred generally time shipment including supply commercial products alliance partners principal end customer sale however certain revenue nonus businesses recognized date receipt customer alliance revenue related abilify atripla recognized products sold end customer alliance partner royalties based third party sales recognized earned accordance contract terms thirdparty sales reliably measurable collectability reasonably assured refer note alliances detail regarding alliances provisions made time revenue recognition expected sales returns discounts rebates estimated sales allowances based historical experience updated changes facts circumstances including impact applicable healthcare legislation provisions recognized reduction revenuewhen new product extension existing line product historical experience products similar therapeutic category revenue deferred right return longer exists sufficient historical experience estimate sales returns developed income taxes provision income taxes includes income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax basis assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made tax benefits recognized uncertain tax position likely tax position sustained examination taxing authorities based technical merits position tax benefit recognized financial statements particular tax position based largest benefit likely realized upon settlement cash cash equivalents cash cash equivalents include us treasury securities government agency securities bank deposits time deposits money market funds cash equivalents consist highly liquid investments original maturities three months less time purchase recognized cost approximates fair value marketable securities investments companies marketable securities classified availableforsale date purchase reported fair value fair value determined based observable market quotes valuation models using assessments counterparty credit worthiness credit default risk underlying security overall capital market liquidity investments less owned companies accounted using equity method accounting ability exercise significant influence maintained share net income losses equity investments included equity net income affiliates incomeexpense equity investments reviewed impairment assessing decline market value investment carrying value temporary considers intent ability retain investment length time extent market value less cost financial condition investee inventory valuation inventories stated lower average cost market property plant equipment depreciation expenditures additions renewals improvements capitalized cost depreciation computed straightline method based estimated useful lives related assets ranging years buildings years machinery equipment fixtures impairment longlived assets current facts circumstances periodically evaluated determine carrying value depreciable assets held used may recoverable circumstances exist estimate undiscounted future cash flows generated longlived asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques using level fair value inputs including discounted value estimated future cash flows capitalized software eligible costs obtain internal use software significant systems projects capitalized amortized estimated useful life software insignificant costs obtain software projects expensed incurred business combinations businesses acquired consolidated upon obtaining control acquiree fair value assets acquired liabilities assumed recognized date acquisition excess purchase price estimated fair values net assets acquired recognized goodwill legal audit business valuation business acquisition costs expensed incurred goodwill acquired inprocess research development intangible assets fair value intangible assets typically determined using income method utilizing level fair value inputs market participant valuations assume global view considering potential jurisdictions indications based discounted aftertax cash flow projections risk adjusted estimated probability technical regulatory success iprd finitelived intangible assets including licenses developed technology rights iprd projects reach commercialization amortized straightline basis estimated useful life estimated useful lives determined considering period assets expected contribute future cash flows goodwill tested least annually impairment assessing qualitative factors performing quantitative analysis determining whether likely fair value net assets carrying amounts examples qualitative factors assessed include share price financial performance compared budgets longterm financial plans macroeconomic industry market conditions well substantial excess fair value carrying value net assets annual impairment test performed prior year relevant factor assessed individually aggregate iprd tested impairment annual basis frequently events occur circumstances change would indicate potential reduction fair values assets carrying value carrying value iprd determined exceed fair value impairment loss recognized difference finitelived intangible assets tested impairment facts circumstances suggest carrying value asset may recoverable carrying value exceeds projected undiscounted pretax cash flows intangible asset impairment loss equal excess carrying value estimated fair value discounted aftertax cash flows recognized restructuring restructuring charges recognized result actions streamline operations rationalize manufacturing facilities estimating impact restructuring plans including future termination benefits exit costs requires judgment actual results could vary estimates contingencies loss contingencies legal proceedings claims may occur wide range matters including government investigations shareholder lawsuits product environmental liability contractual claims tax matters accruals recognized probable liability incurred amount loss reasonably estimated gain contingencies including contingent proceeds related divestitures recognized realized legal fees expensed incurred derivative financial instruments derivatives used principally management interest rate foreign currency exposures held used trading purposes derivatives recognized fair value changes fair value recognized earnings unless specific hedge criteria met derivative designated fair value hedge changes fair value derivative hedged item attributable hedged risk recognized earnings derivative designated cash flow hedge effective portions changes fair value derivative reported accumulated comprehensive incomeloss oci subsequently recognized earnings hedged item affects earnings cash flows classified consistent underlying hedged item derivatives designated assigned hedges forecasted transactions specific assets specific liabilities hedged assets liabilities sold extinguished forecasted transactions hedged longer probable occur gain loss immediately recognized earnings nonderivative instruments primarily euro denominated longterm debt also designated hedges net investments foreign affiliates effective portion designated nonderivative instrument recognized foreign currency translation section oci ineffective portion recognized earnings shipping handling costs shipping handling costs included marketing selling administrative expenses million million million advertising product promotion costs advertising product promotion costs expensed incurred foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized oci research development research development costs expensed incurred clinical study costs accrued service periods specified contracts adjusted necessary based upon ongoing review level effort costs actually incurred strategic alliances third parties provide rights develop manufacture market andor sell pharmaceutical products rights owned party research development recognized net reimbursements connection alliance agreements recently issued accounting standards april financial accounting standards board fasb issued amended guidance use presentation discontinued operations entity 's consolidated financial statements new guidance restricts presentation discontinued operations business circumstances disposal business operations represents strategic shift major effect entity 's operations financial results guidance becomes effective january adoption prospective basis may fasb issued new standard related revenue recognition requires entity recognize amount revenue expects entitled transfer promised goods services customers new standard replace existing revenue recognition standards us gaap becomes effective january early adoption permitted new standard applied retrospectively prior reporting period presented retrospectively cumulative effect change recognized date initial application retained earnings company assessing potential impact new standard financial reporting yet selected transition method note business segment information bms operates single segment engaged discovery development licensing manufacturing marketing distribution sale innovative medicines help patients prevail serious diseases global research development organization supply chain organization responsible development delivery products market regional commercial organizations used distribute sell product business also supported global corporate staff functions segment information consistent financial information regularly reviewed chief executive officer purposes evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods products sold principally wholesalers lesser extent directly distributors retailers hospitals clinics government agencies pharmacies gross revenues three largest pharmaceutical wholesalers us percentage global gross revenues follows mckesson corporation cardinal health inc amerisourcebergen corporation selected geographic area information follows total revenues property plant equipment dollars millions united states europe rest world othera total total revenues include royalties alliancerelated revenues products sold regional commercial organizations total revenues key products follows year ended december dollars millions virology baraclude entecavir hepatitis c franchisea reyataz atazanavir sulfate sustiva efavirenz franchiseb oncology erbitux cetuximab opdivo nivolumab sprycel dasatinib yervoy ipilimumab neuroscience abilify aripiprazolec immunoscience orencia abatacept cardiovascular eliquis apixaban diabetes allianced mature products othere total revenues includes daklinza daclatasvir revenues million sunvepra asunaprevir revenues million b includes alliance revenues million million million c includes alliance revenues million million million includes bydureon exenatide extendedrelease injectable suspension byetta exenatide farxigaxigduo dapagliflozindapagliflozin metformin hydrochloride onglyzakombiglyze saxagliptinsaxagliptin metformin myalept metreleptin symlin pramlintide acetate bms sold diabetes business astrazeneca february e includes plavix clopidogrel bisulfate revenues million million million additionally includes avaproavalide irbesartanirbesartanhydrochlorothiazide revenues million million million note alliances bms enters collaboration arrangements third parties development commercialization certain products although arrangements unique nature parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities bms may either inlicense intellectual property owned party outlicense intellectual property party arrangements also typically include research development manufacturing andor commercial activities cover single investigational compound commercial product multiple compounds andor products various life cycle stages refer collaborations alliances partners alliance partners several key products abilify sprycel sustiva atripla eliquis erbitux opdivo well products comprising diabetes alliance discussed certain mature brands included alliance arrangements payments alliance partners accounted presented results operations considering specific nature payment underlying activities payments relate multiple alliance activities including transfer rights separated individual units accounting standalone value activities occur life arrangements situations arrangement consideration allocated activities rights relative selling price basis multiple alliance activities rights standalone value combined single unit accounting common activities bms alliance partners presented results operations follows bms principal end customer sale product sales included net product sales bms 's alliance partner principal end customer sale bms 's contractual share thirdparty sales andor royalty income included alliance revenue sale commercial products considered part bms 's ongoing major central operations refer revenue recognition included note accounting policies information regarding recognition criteria amounts payable bms alliance partners principal end customer sale supply commercial products included alliance revenue sale commercial products considered part bms 's ongoing major central operations amounts payable bms alliance partners profit sharing royalties salesbased fees included cost products sold incurred cost reimbursements parties recognized incurred included cost products sold marketing selling administrative expenses advertising product promotion expenses research development expenses based underlying nature related activities subject reimbursement upfront contingent development approval milestones payable bms alliance partners investigational compounds commercial products deferred amortized shorter contractual term periods related compounds products expected contribute future cash flows amortization presented consistent nature payment arrangement example amounts received investigational compounds presented incomeexpense activities performed time related sale commercial products part bmss ongoing major central operations amounts received commercial products presented alliance revenue sale commercial products considered part bmss ongoing major central operations except astrazeneca plc astrazeneca alliance pertaining amylin products see discussion specific astrazeneca alliance disclosure herein upfront contingent approval milestones payable bms alliance partners commercial products capitalized amortized shorter contractual term periods related products expected contribute future cash flows amortization included cost products sold upfront contingent milestones payable bms alliance partners prior regulatory approval expensed incurred included research development expenses equity net income affiliates included incomeexpense payments bms alliance partners presented cash flows operating activities except otherwise described selected financial information pertaining alliances follows including net product sales bms principal thirdparty customer sale products subject alliance expenses summarized include amounts attributed activities products alliance payments alliance partners related amortization payments deferred capitalized year ended december dollars millions revenues alliances net product sales alliance revenues total revenues payments tofrom alliance partners cost products sold marketing selling administrative advertising product promotion research development incomeexpense noncontrolling interest pretax selected alliance balance sheet information december dollars millions receivables alliance partners accounts payable alliance partners deferred income alliancesa includes deferred income classified liabilities related assets heldforsale million december specific information pertaining significant alliances discussed including nature purpose significant rights obligations parties specific accounting policy elections income statement classification amounts attributable payments parties otsuka bms worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote abilify excluding certain asian countries us portion agreement amended expires upon expected loss product exclusivity april agreement expired european union eu countries june nonus country exclusive right sell abilify agreement expires later april loss exclusivity country parties actively participate joint executive governance operating committees although otsuka assumed responsibility providing funding sales force efforts effective january us amendment bms responsible funding certain operating expenses various annual limits bms purchases active pharmaceutical ingredient api otsuka completes manufacture product subsequent sale third party customers us certain countries otsuka assumed responsibility providing funding sales force efforts eu effective april bms also provides certain services including distribution customer management pharmacovigilence otsuka principal thirdparty product sales us principal eu prior termination june bms principal thirdparty product sales exclusive distributor exclusive right sell abilify alliance revenue recognized bmss share total net sales thirdparty customers territories us bmss contractual share beginning january bmss contractual share changed percentages total us net sales set forth table assessment bms 's expected annual contractual share completed quarterly reporting period adjusted based upon reported us abilify net sales year end bms 's annual contractual share alliance revenue recognized interim period quarter exceed amounts due contract annual us net sales bms share us net sales billion billion billion billion billion billion billion billion billion excess billion eu bmss contractual share thirdparty net sales countries us alliance revenue recognized abilify shipped risks rewards ownership transferred thirdparty customers terms us amendment bms paid otsuka million amortized reduction alliance revenue expected loss us exclusivity april unamortized balance included assets otsuka receives royalty based total us net sales included cost products sold otsuka responsible us expenses related commercialization abilify bms otsuka also alliance sprycel ixempra ixabepilone us japan eu parties actively participate various governance committees bms control decision making parties copromote product bms responsible development manufacture product also principal endcustomer product sales fee paid otsuka based following percentages annual net sales sprycel ixempra net sales million million million million million million billion excess billion annual periods otsuka contributes first million certain commercial operational expenses relating oncology products oncology territory costs excess million summarized financial information related alliance follows year ended december dollars millions revenues otsuka alliances net product sales alliance revenuesa total revenues payments tofrom otsuka cost products sold oncology fee royalties amortization intangible assets cost product supply cost reimbursements tofrom otsuka recognized cost products sold marketing selling administrative advertising product promotion research development incomeexpense selected alliance balance sheet information december dollars millions assets extension payment includes amortization extension payment reduction alliance revenue million astrazeneca prior diabetes business divestiture discussed bms alliance astrazeneca consisting three worldwide codevelopment commercialization agreements covering onglyza related combination products sold various names farxiga related combination products beginning august bms 's acquisition amylin pharmaceuticals inc amylin amylin 's portfolio products including bydureon byetta symlin myalept well certain assets owned amylin including manufacturing facility located west chester ohio coexclusive license rights product products underlying agreement granted astrazeneca exchange upfront payment potential milestone payments parties assumed certain obligations actively participate alliance parties actively participated joint executive committee various operating committees joint responsibilities research development distribution sales marketing activities alliance using resources infrastructures bms manufactured products three alliances principal endcustomer product sales substantially countries alliance agreement rights transferred astrazeneca standalone value rights sold separately bms party could astrazeneca received benefit delivered rights without fulfillment ongoing obligations bms alliance agreements including exclusive supply arrangement global alliance treated single unit accounting result upfront proceeds subsequent contingent milestone proceeds amortized life related products bms received billion nonrefundable upfront payment astrazeneca consideration entering amylin alliance astrazeneca exercised option equal governance rights certain key strategic financial decisions regarding amylin alliance paid bms million consideration payments accounted deferred income amortized based relative fair value predominant elements included alliance estimated useful lives intangible assets related bydureon estimated useful life years byetta estimated useful life years symlin estimated life years myalept estimated useful life years amylin manufacturing plant estimated useful life years amortization presented reduction cost products sold alliance assets acquired shortly commencement alliance astrazeneca entitled share proceeds sale assets amortization acquired amylin intangible assets manufacturing plant also presented cost products sold bms entitled reimbursements capital expenditures related acquired amylin manufacturing facility bms astrazeneca also shared certain tax attributes related amylin alliance prior termination alliance bms received nonrefundable upfront milestone licensing payments million related onglyza million related farxiga amortization onglyza farxiga deferred income included income onglyza farxiga commercial products commencement alliance parties also shared commercialization development expenses equally well profits losses february bms astrazeneca terminated alliance agreements bms sold astrazeneca substantially diabetes business comprising alliance divestiture included shares amylin resulting transfer ohio manufacturing facility intellectual property related onglyza farxiga including bms 's interest outlicensing agreement onglyza japan future purchase bmss manufacturing facility located mount vernon indiana substantially employees dedicated diabetes business transferred astrazeneca sale business completed jurisdictions bms astrazeneca entered several agreements connection sale including supply agreement development agreement transitional services agreement agreements bms obligated supply certain products including active product ingredients onglyza farxiga perform ongoing development activities certain clinical trial programs provide transitional services accounting financial services customer service distribution regulatory development information technology certain administrative services various periods order facilitate orderly transfer business operations annual costs attributed development agreement expected exceed approximately million consideration transaction includes billion payment closing contingent regulatory salesbased milestone payments billion including million related approval milestones million related salesbased milestones payable royalty payments based net sales payments million certain assets transferred astrazeneca astrazeneca also pay bms required product supply price approximating product cost well negotiated transitional service fees royalty rates net sales follows onglyza farxiga worldwide net sales million onglyza farxiga worldwide net sales million amylin products us net sales stock asset purchase agreement contains multiple elements delivered subsequent closing transaction including china diabetes business transferred third quarter mount vernon indiana manufacturing facility activities development supply agreements elements determined standalone value result portion consideration received closing allocated undelivered elements using relative selling price method determining best estimated selling price element remaining amount consideration included calculation gain sale diabetes business contingent milestone royalty payments similarly allocated among underlying elements amounts determined payable bms amounts allocated sale business immediately recognized results operations amounts allocated elements recognized results operations extent element delivered consideration billion accounted substantially first quarter including royalties million contingent regulatory milestone payments related approval farxiga us japan approximately billion consideration allocated sale business remaining million allocated undelivered elements described consideration includes million earned royalties including million allocated elements delivered gain sale diabetes business million including million third quarter resulting primarily transfer china diabetes business astrazeneca gain based difference consideration allocated sale business excluding royalties net transaction fees carrying value diabetes business net assets including million allocation goodwill reversal million net deferred tax liabilities attributed amylin consideration allocated mount vernon indiana manufacturing facility continue deferred transferred astrazeneca consideration allocated development supply agreements continue amortized applicable service periods amortization deferred income attributed development agreement included income sale services considered part bmss ongoing major central operations revenues attributed supply agreement included alliance revenues consideration transaction presented cash flow purposes based allocation process described either investing activity attributed sale business related assets operating activity attributed transitional services supply arrangement development agreement summarized financial information related astrazeneca alliances follows year ended december dollars millions revenues astrazeneca alliances net product sales alliance revenues total revenues payments tofrom astrazeneca cost products sold profit sharing amortization deferred income cost reimbursements tofrom astrazeneca recognized cost products sold marketing selling administrative advertising product promotion research development incomeexpense amortization deferred income provision restructuring royalties transitional services gain sale business selected alliance cash flow information deferred income business divestitures proceeds selected alliance balance sheet information december dollars millions deferred income attributed nonrefundable upfront milestone licensing receiptsa assets yet transferred astrazeneca services yet performed astrazeneca included liabilities related assets heldforsale december gilead bms gilead sciences inc gilead joint ventures us us canada europe develop commercialize atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg combining sustiva product bms truvada emtricitabine tenofovir disoproxil fumarate product gilead joint ventures consolidated gilead parties actively participate joint executive committee various operating committees direct oversight activities joint ventures joint ventures purchase sustiva truvada api bulk form parties complete finishing atripla joint ventures gilead sell distribute atripla principal thirdparty customer sales parties longer coordinate joint promotional activities alliance revenue recognized atripla include bulk efavirenz component atripla based relative ratio average respective net selling prices truvada sustiva alliance revenue deferred related alliance receivable recognized combined product sold thirdparty customers europe following loss exclusivity sustiva effective january percentage atripla net sales europe recognized bms equal difference average net selling prices atripla truvada alliance continue europe either party terminates arrangement last patent expiration occurs atripla truvada sustiva us agreement may terminated gilead upon launch generic version sustiva bms upon launch generic version truvada event gilead terminates agreement upon loss exclusivity sustiva bms receive quarterly royalty payment months following termination payment first months following termination equal atripla net sales multiplied ratio difference average net selling prices atripla truvada atripla average net selling price second third years following termination payment bms reduced respectively atripla net sales multiplied price ratio described bms continue supply sustiva cost plus markup joint ventures threeyear period unless either party elects terminate supply arrangement summarized financial information related alliance follows year ended december dollars millions revenues gilead alliances alliance revenues equity net loss affiliates selected alliance balance sheet information december dollars millions deferred income lilly bms epidermal growth factor receptor egfr commercialization agreement eli lilly company lilly lillys subsidiary imclone co development copromotion erbitux us canada japan egfr agreement parties actively participate joint executive committee various operating committees share responsibilities research development using resources infrastructures respect erbitux lilly manufactures bulk requirements cetuximab facilities filling finishing performed third party bms oversight responsibility bms responsible promotional efforts north america although lilly right copromote expense bms also co development copromotion rights canada japan bms principal thirdparty customer sales north america pays lilly distribution fee erbitux net sales north america plus share certain royalties paid lilly agreement expires erbitux north america september bms shared rights erbitux japan agreement lilly merck kgaa received pretax profit merck kgaas net sales erbitux japan shared equally lilly december bms agreed transfer cocommercialization rights japan merck kgaa may exchange future royalties included income earned march bms lilly terminated arrangement necitumumab imcf rights returning lilly discovered imclone necitumumab fully human monoclonal antibody part alliance bms lilly license acquisition costs million associated erbitux alliance agreement amortized summarized financial information related alliance follows year ended december dollars millions revenues lilly alliance net product sales alliance revenues total revenues payments tofrom lilly cost products sold distribution fees royalties amortization intangible asset cost product supply cost reimbursements tofrom lilly incomeexpense japan commercialization fee selected alliance balance sheet information december dollars millions intangible assets nonrefundable upfront milestone licensing payments bms acquired amylin pharmaceuticals inc amylin august see note acquisitions information amylin previously entered settlement termination agreement lilly regarding alliance global development commercialization byetta bydureon exenatide products parties agreed transition full responsibility products amylin transition us operations completed prior acquisition transition nonus operations majority markets completed april terminating lilly 's nonus exclusive right promissory notes assumed acquisition amylin aggregating billion repaid lilly sanofi september bms sanofi restructured terms codevelopment cocommercialization agreements plavix avaproavalide effective january sanofi assumed essentially worldwide operations alliance exception plavix us puerto rico alliance plavix markets continues unchanged december terms original alliance arrangements described exchange rights transferred sanofi bms receives quarterly royalties january december terminal payment sanofi million end beginning royalties received sanofi territory covering americas australia optout markets former development royalties presented alliance revenues million million development optout royalty income million included incomeexpense development royalty expense due sanofi million presented cost products sold million presented incomeexpense royalties attributed territory covering europe asia continue earned territory partnership included equity net income affiliates equity net income affiliates included million profit deferred prior restructuring agreement alliance revenues attributed supply irbesartan api sanofi million million million supply arrangement irbesartan expires prior restructuring bmss worldwide alliance sanofi codevelopment cocommercialization avaproavalide plavix operated framework two geographic territories one americas principally us canada puerto rico latin american countries australia europe asia two territory partnerships managed central expenses marketing research development royalties supply finished product individual countries bms acted operating partner owned majority controlling interest territory covering americas australia consolidated country partnership results territory sanofis share results reflected noncontrolling interest bms also recognized net product sales comarketing countries outside territory eg italy irbesartan germany greece spain sanofi acted operating partner owned majority controlling interest territory covering europe asia bms ownership interest territory summarized financial information related alliance follows year ended december dollars millions revenues sanofi alliances net product sales alliance revenues total revenues payments tofrom sanofi cost product supply cost products sold royalties equity net income affiliates incomeexpense noncontrolling interest pretax selected alliance cash flow information distributions tofrom sanofi noncontrolling interest distributions sanofi investment affiliates selected alliance balance sheet information december dollars millions investment affiliates territory covering europe asiaa noncontrolling interest included alliance receivables following summarized financial information interests partnerships sanofi territory covering europe asia consolidated accounted using equity method year ended december dollars millions net sales gross profit net income cost products sold territory covering europe asia includes discovery royalties million million million paid directly sanofi expenses shared based applicable ownership percentages current assets current liabilities include approximately million million million related receivablespayables attributed cash distributions bms sanofi well intercompany balances partnerships within territory pfizer bms pfizer inc pfizer maintain worldwide codevelopment cocommercialization agreement eliquis anticoagulant discovered bms pfizer funds development costs depending study companies share profits losses equally global basis certain countries pfizer commercializes eliquis pays bms compensation based percentage net sales upon entering agreement coexclusive license rights product granted pfizer exchange upfront payment potential milestone payments parties assumed certain obligations actively participate alliance actively participate joint executive committee various operating committees joint responsibilities research development distribution sales marketing activities alliance using resources infrastructures bms manufactures product alliance principal endcustomer product sales countries determined rights transferred pfizer standalone value rights sold separately bms party could pfizer receive benefit delivered rights without fulfillment ongoing obligations bms alliance agreement including exclusive supply arrangement global alliance treated single unit accounting upfront proceeds subsequent contingent milestone proceeds amortized life related product bms received million nonrefundable upfront milestone licensing payments related eliquis date amortization eliquis deferred income included income eliquis commercial product commencement alliance summarized financial information related alliance follows year ended december dollars millions revenues pfizer alliance net product sales alliance revenues total revenues payments tofrom pfizer cost products sold profit sharing cost reimbursements tofrom pfizer incomeexpense amortization deferred income selected alliance cash flow information deferred income selected alliance balance sheet information december dollars millions deferred income reckitt benckiser group may bms reckitt benckiser group plc reckitt entered threeyear alliance several overthecounterproducts sold primarily mexico brazil net sales products approximately million reckitt received right sell distribute market products may certain responsibilities related regulatory matters covered territory bms receives royalties net sales products exclusively supplies certain products reckitt cost plus markup certain limited assets including market authorizations certain employees directly attributed business transferred reckitt start alliance period bms retained ownership assets related business including trademarks covering products bms also granted reckitt option acquire trademarks inventory certain assets exclusively related products end alliance period price determined based multiple sales plus cost remaining inventory held bms time april alliance modified provide option reckitt purchase bms manufacturing facility located mexico primarily dedicated products included alliance options exercised together substantially employees facility expected transferred reckitt option exercised option exercised assets previously transferred reckitt revert back bms option may exercised reckitt may november case closing would expected occur may nonrefundable upfront proceeds million received bms allocated two units accounting including rights transferred reckitt fair value option purchase remaining assets using best estimate selling price elements considering various market factors market factors included analysis estimated excess fair value business potential purchase price option exercised fair value option determined using level inputs included liabilities million charge included expenses increase fair value option million amount allocated rights transferred reckitt amortized alliance revenue contractual term summarized financial information related alliance follows year ended december dollars millions revenues reckitt alliance alliance revenues selected alliance cash flow information deferred income changes operating assets liabilities selected alliance balance sheet information december dollars millions deferred income medicines company february bms medicines company entered twoyear alliance recothrom recombinant thrombin use topical hemostat control nonarterial bleeding surgical procedures previously acquired bms connection acquisition zymogenetics inc net product sales recothrom million medicines company received right sell distribute market recothrom global basis two years certain responsibilities related regulatory matters covered territory bms exclusively supplies recothrom medicines company cost plus markup receives royalties net sales recothrom certain employees directly attributed business certain assets transferred medicines company start alliance period including biologics license application related regulatory assets bms retained assets related recothrom including patents trademarks inventory bms also granted medicines company option acquire patents trademarks inventory certain assets exclusively related recothrom price determined based multiple sales plus cost remaining inventory held bms time medicines company exercised option acquired business million february see note assets heldforsale information nonrefundable upfront proceeds million received bms allocated two units accounting including rights transferred medicines company fair value option purchase remaining assets using best estimate selling price elements considering various market factors market factors included analysis estimated excess fair value business potential purchase price option exercised fair value option million december determined using level inputs included accrued expenses amount allocated rights transferred medicines company amortized alliance revenue contractual term summarized financial information related alliance follows year ended december dollars millions revenues medicines company alliance alliance revenues selected alliance cash flow information deferred income changes operating assets liabilities selected alliance balance sheet information december dollars millions deferred income valeant october bms pharmaswiss sa whollyowned subsidiary valeant pharmaceuticals international inc valeant entered alliance certain mature brand products europe valeant received right sell distribute market products europe december certain responsibilities related regulatory matters covered territory bms exclusively supplies products valeant cost plus markup bms also granted valeant option acquire trademarks intellectual property exclusively related products price determined based multiple sales valeant exercised option acquired business million january nonrefundable upfront proceeds million received bms allocated two units accounting including rights transferred valeant fair value option purchase remaining assets using best estimate selling price elements considering various market factors market factors included analysis estimated excess fair value business potential purchase price option exercised fair value option determined using level inputs included accrued expenses million charge included expenses increase fair value option million amount allocated rights transferred valeant amortized alliance revenue contractual term summarized financial information related alliance follows year ended december dollars millions revenues valeant alliance net product sales alliance revenues total revenues selected alliance cash flow information deferred income changes operating assets liabilities selected alliance balance sheet information december dollars millions deferred income ono bms ono pharmaceutical co ltd ono alliance agreement develop commercialize opdivo antipd human monoclonal antibody investigated anticancer treatment bms exclusive right develop manufacture commercialize opdivo territories worldwide except japan south korea taiwan ono responsible development commercialization prior amendment discussed ono entitled receive royalties following regulatory approvals territories excluding three countries listed royalty rates north america applicable territories alliance agreement amended july provide additional collaboration activities japan south korea taiwan pertaining opdivo several bms compounds including ipilimumab lirilumab urelumab bms antilag parties right obligation jointly develop commercialize compounds bms responsible supply product profits losses development costs shared equally combination therapies involving compounds parties otherwise sharing activities involving one partys compounds bms ono also codevelop cocommercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulations jointly promoted parties assigned customer accounts bms responsible product supply copromotion fee paid party sale made partys assigned customer summarized financial information related alliance follows year ended december dollars millions revenues ono alliances net product sales alliance revenues total revenues payments tofrom ono cost products sold copromotion fee cost reimbursements tofrom ono recognized research development fstar october bms entered agreement fstar alpha ltd fstar agreement provides bms exclusive option purchase fstar alpha ltd phase ready lead asset fs targeted therapy development treatment breast gastric cancer among welldefined population herpositive patients bms paid million fstar shareholders option fee certain licensing rights included research development expenses responsible conducting funding development fs option exercisable bms 's discretion expires upon earlier days following obtaining proof concept june additional million payable upon exercise option plus additional aggregate consideration million contingent development regulatory approval milestone payments us europe bms obligated provide additional financial support fstar fstar determined business defined asc business combinations result contingent consideration included purchase price goodwill recognized however fstar variable interest entity equity holders lack characteristics controlling financial interest bms determined primary beneficiary power direct activities significantly directly impacting economic performance entity option rights described upon consolidation noncontrolling interest credited million reflect fair value fs iprd asset million deferred tax liabilities note acquisitions ipierian inc acquisition april bms acquired outstanding shares ipierian inc ipierian biotechnology company focused new treatments tauopathies class neurodegenerative diseases acquisition provides bms full rights ipn preclinical monoclonal antibody treat progressive supranuclear palsy tauopathies consideration includes upfront payment million contingent development regulatory milestone payments million future royalties net sales acquired preclinical assets approved commercialized significant ipierian processes acquired therefore transaction accounted asset acquisition ipierian determined business upfront payment allocated ipn million included research development expenses remaining million allocated deferred tax assets net operating losses tax credit carryforwards amylin pharmaceuticals inc acquisition august bms acquired outstanding shares amylin biopharmaceutical company focused discovery development commercialization innovative medicines treat diabetes metabolic diseases acquisition costs million included expenses bms obtained full us commercialization rights amylins two primary commercialized assets bydureon onceweekly diabetes treatment byetta daily diabetes treatment glucagonlike peptide glp receptor agonists approved certain countries improve glycemic control adults type diabetes bms also obtained full commercialization rights symlin amylinomimetic approved us adjunctive therapy mealtime insulin treat diabetes goodwill generated acquisition primarily attributed expansion diabetes franchise iprd attributed metreleptin analog human hormone leptin studied developed treatment diabetes andor hypertriglyceridemia pediatric adult patients inherited acquired lipodystrophy estimated useful life cash flows utilized value metreleptin assumed initial positive cash flows commence shortly expected receipt regulatory approvals subject trial results see note alliancesastrazeneca discussion sale company 's diabetes business including amylin astrazeneca comprised global diabetes alliance inhibitex inc acquisition february bms acquired outstanding shares inhibitex inc inhibitex clinicalstage biopharmaceutical company focused developing products prevent treat serious infectious diseases acquisition costs million included expense bms obtained inhibitexs lead asset inx oral nucleotide polymerase nsb inhibitor phase ii development treatment chronic hepatitis c virus infections goodwill generated acquisition primarily attributed potential offer full portfolio therapy choices hepatitis virus infections well provide additional levels sustainability bmss virology pipeline iprd primarily attributed inx inx expected effective used combination therapy assumed market participants would inherently maintain franchise synergies attributed maximizing cash flows existing virology pipeline assets cash flows utilized value inx included synergies also assumed initial positive cash flows commence shortly expected receipt regulatory approvals subject trial results august company discontinued development inx interest patient safety result company recognized noncash pretax impairment charge billion information discussion impairment charge see note goodwill intangible assets total consideration transferred allocation acquisition date fair values assets acquired liabilities assumed amylin inhibitex acquisitions follows dollars millions identifiable net assets amylin inhibitex cash marketable securities inventory property plant equipment developed technology rights iprd assets debt obligations liabilities deferred income taxes total identifiable net assets goodwill total consideration transferred cash paid acquisition amylin included payments billion outstanding common stockholders million holders stock options restricted stock units including million attributed accelerated vesting accounted stock compensation expense results operations cash flows acquired companies included consolidated financial statements acquisition date pro forma supplemental financial information provided impacts acquisitions material operating results year acquisition goodwill iprd intangible assets valued acquisitions nondeductible tax purposes note assets heldforsale discussed note alliances bms sold diabetes business astrazeneca february previously comprised global alliance diabetes business treated single disposal group heldforsale december writedown required fair value business less costs sell exceeded related carrying value assets heldforsale december related alliances medicines company valeant allocation goodwill based relative fair value businesses divested company 's reporting unit following table provides assets liabilities classified heldforsale december december dollars millions assets receivables inventories deferred income taxes current prepaid expenses property plant equipment goodwill intangible assets assets assets heldforsale liabilities shortterm borrowings current portion longterm debt accounts payable accrued expenses deferred income current accrued rebates returns deferred income noncurrent deferred income taxes noncurrent liabilities liabilities related assets heldforsale note incomeexpense incomeexpense includes year ended december dollars millions interest expense investment income provision restructuring litigation chargesrecoveries equity net income affiliates outlicensed intangible asset impairment gain sale product lines businesses assets alliance licensing income pension curtailments settlements special termination benefits incomeexpense note restructuring following provision restructuring year ended december dollars millions employee termination benefits exit costs provision restructuring restructuring charges included employee termination benefits manufacturing selling administrative research development workforce reductions across geographic regions approximately restructuring actions primarily related specialty care transformation initiatives designed create simplified organization across functions geographic markets sales force reductions several european countries following restructuring sanofi otsuka alliance agreements subject local regulations costs recognized completion discussions works councils additional costs million expected incurred specialty care transformation initiatives following table represents activity employee termination exit cost liabilities year ended december dollars millions liability january charges change estimates provision restructuring foreign currency translation amylin acquisition liabilities related assets heldforsale spending liability december note income taxes provisionbenefit income taxes consisted year ended december dollars millions current us nonus total current deferred us nonus total deferred total provisionbenefit effective tax rate reconciliation effective taxbenefit rate us statutory federal income tax rate earnings income taxes dollars millions earningsloss income taxes us nonus total us statutory rate foreign tax effect certain operations ireland puerto rico switzerland us tax effect capital losses us federal state foreign contingent tax matters us federal research based credits goodwill related diabetes divestiture us branded prescription drug fee rd charge state local taxes net valuation allowance foreign effective tax rate lower us statutory rate primarily attributable undistributed earnings certain foreign subsidiaries considered expected indefinitely reinvested offshore us taxes provided approximately billion undistributed earnings foreign subsidiaries december undistributed earnings primarily relate operations ireland puerto rico operate favorable tax grants scheduled expire prior undistributed earnings repatriated us future determined earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes provided reforms us tax laws related foreign earnings proposed adopted may increase taxes could reduce results operations cash flows divestiture diabetes business resulted million capital loss tax benefit sale amylin shares additional reserves million established certain transfer pricing matters related tax periods goodwill allocated diabetes business divestiture us branded prescription drug fee research development charge acquisition ipierian deductible tax purposes retroactive reinstatement us federal research development credit resulted additional tax credits million tax insolvency inhibitex resulted million capital loss tax benefit orphan drug credits included us federal research based credits periods presented deferred taxes valuation allowance components current noncurrent deferred income tax assetsliabilities follows december dollars millions deferred tax assets foreign net operating loss carryforwards milestone payments license fees deferred income us capital loss carryforwards us federal net operating loss carryforwards pension postretirement benefits state net operating loss credit carryforwards intercompany profit inventory items us federal tax credit carryforwards foreign deferred tax assets sharebased compensation legal settlements repatriation foreign earnings internal transfer intellectual property total deferred tax assets valuation allowance net deferred tax assets deferred tax liabilities depreciation acquired intangible assets total deferred tax liabilities deferred tax assets net recognized assets heldforsale deferred income taxes current deferred income taxes noncurrent income taxes payable current liabilities related assets heldforsale income taxes payable noncurrent total us federal net operating loss carryforwards million december carryforwards acquired result certain acquisitions subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning us federal tax credit carryforwards expire varying amounts beginning realization us federal tax credit carryforwards dependent generating sufficient domesticsourced taxable income prior expiration capital loss available million carried back carryforward amount expires various amounts beginning foreign state net operating loss carryforwards expire varying amounts beginning certain amounts unlimited lives december valuation allowance million established following items million primarily foreign net operating loss tax credit carryforwards million state deferred tax assets including net operating loss tax credit carryforwards million us federal net operating loss carryforwards million us federal state capital losses changes valuation allowance follows year ended december dollars millions balance beginning year provision utilization foreign currency translation acquisitions balance end year income tax payments million million million current tax benefit realized result stock related compensation credited capital excess par value stock million million million business conducted various countries throughout world subject tax numerous jurisdictions significant number tax returns filed subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported requiring several years resolve liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation reconciliation beginning ending amount gross unrecognized tax benefits follows year ended december dollars millions balance beginning year gross additions tax positions related current year gross additions tax positions related prior years gross additions tax positions assumed acquisitions gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance end year additional information regarding unrecognized tax benefits follows year ended december dollars millions unrecognized tax benefits recognized would impact effective tax rate accrued interest accrued penalties interest expense penalty expensebenefit accrued interest penalties payable unrecognized tax benefits included either current noncurrent us foreign income taxes payable interest penalties related unrecognized tax benefits included income tax expense effective january bms adopted update fasb clarified existing guidance presentation unrecognized tax benefits various qualifying tax benefit carryforwards exist including unrecognized tax benefit presented reduction deferred tax assets liability non current deferred tax assets income tax liabilities reduced million upon adoption bms currently examination number tax authorities including limited major tax jurisdictions listed table proposed adjustments tax issues transfer pricing certain tax credits deductibility certain expenses bms estimates reasonably possible total amount unrecognized tax benefits december decrease range approximately million million next twelve months result settlement certain tax audits events expected change unrecognized tax benefits primarily settlement related involve payment additional taxes adjustment certain deferred taxes andor recognition tax benefits reasonably possible new issues raised tax authorities may increase unrecognized tax benefits however estimate increases reasonably made time bms believes adequately provided open tax years tax jurisdiction following summary major tax jurisdictions tax authorities may assert additional taxes based upon tax years currently audit subsequent years likely audited us canada france germany italy mexico note earnings per share year ended december amounts millions except per share data net earnings attributable bms earnings attributable unvested restricted shares net earnings attributable bms common shareholders earnings per share basic weightedaverage common shares outstanding basic contingently convertible debt common stock equivalents incremental shares attributable sharebased compensation plans weightedaverage common shares outstanding diluted earnings per share diluted antidilutive weightedaverage equivalent shares stock incentive plans note financial instruments fair value measurements financial instruments include cash cash equivalents marketable securities accounts receivable payable debt instruments derivatives changes exchange rates interest rates create exposure market risk certain derivative financial instruments used available costeffective basis hedge underlying economic exposure instruments qualify cash flow net investment fair value hedges upon meeting certain criteria including effectiveness offsetting hedged exposures changes fair value derivatives qualify hedge accounting recognized earnings occur derivative financial instruments used trading purposes financial instruments subject counterparty credit risk considered part overall fair value measurement counterparty credit risk monitored ongoing basis mitigated limiting amounts outstanding individual counterparty utilizing conventional derivative financial instruments entering agreements counterparties meet high credit quality standards consolidated financial statements would materially impacted counterparty failed perform according terms agreement collateral required party whether derivatives asset liability position terms agreements fair value measurements fair values financial instruments classified one following categories level inputs utilize nonbinding quoted prices unadjusted active markets accessible measurement date identical assets liabilities fair value hierarchy provides highest priority level inputs level inputs utilize observable prices similar instruments nonbinding quoted prices identical similar instruments nonactive markets observable inputs corroborated market data substantially full term assets liabilities instruments include corporate debt securities certificates deposit money market funds foreign currency forward contracts interest rate swap contracts equity funds fixed income funds longterm debt additionally certain corporate debt securities utilize thirdparty matrix pricing model using significant inputs corroborated market data substantially full term assets equity fixed income funds primarily invested publicly traded securities valued respective net asset value underlying investments significant unfunded commitments restrictions redemptions related equity fixed income funds december level derivative instruments valued using london interbank offered rate libor yield curves less credit valuation adjustments observable forward foreign exchange rates reporting date valuations derivative contracts may fluctuate considerably volatility underlying foreign currencies underlying interest rates driven market conditions duration contract credit adjustment volatility may significant impact valuation interest rate swap contracts resulting changes counterparty credit ratings credit default swap spreads level unobservable inputs used little market data available fair value written options sell assets certain businesses see note alliances discussion based option pricing methodology considers revenue profitability projections volatility discount rates potential exercise price assumptions fair value contingent consideration related acquisition estimated utilizing model considered probability achieving milestone discount rates financial assets liabilities measured fair value recurring basis summarized december december dollars millions level level level total level level level total cash cash equivalents money market securities marketable securities certificates deposit corporate debt securities equity funds fixed income funds auction rate securities ars derivative assets interest rate swap contracts foreign currency forward contracts equity investments derivative liabilities interest rate swap contracts foreign currency forward contracts written option liabilities contingent consideration liability following table summarizes activity financial assets utilizing level fair value measurements written contingent written contingent option consideration ars option consideration dollars millions ars liabilities liability frsa liabilities liability fair value january additions new alliances unrealized gains sales changes fair value fair value december floating rate securities availableforsale securities following table summarizes availableforsale securities gross gross unrealized unrealized gain loss amortized accumulated accumulated dollars millions cost oci oci fair value december certificates deposit corporate debt securities ars equity investments total december certificates deposit corporate debt securities ars total availableforsale securities included current marketable securities million december million december noncurrent availableforsale corporate debt securities mature within five years december except ars equity investments million included assets december fair value option financial assets investments equity fixed income funds offsetting changes fair value certain employee retirement benefits included current marketable securities investment income resulting changes fair value significant qualifying hedges following summarizes fair value outstanding derivatives december december dollars millions balance sheet location notional fair value notional fair value derivatives designated hedging instruments interest rate swap contracts assets interest rate swap contracts liabilities foreign currency forward contracts prepaid expenses foreign currency forward contracts assets foreign currency forward contracts accrued expenses foreign currency forward contracts liabilities cash flow hedges foreign currency forward contracts primarily utilized hedge forecasted intercompany inventory purchase transactions certain foreign currencies contracts designated cash flow hedges effective portion changes fair value reported accumulated oci recognized earnings hedged item affects earnings net gains expected reclassified cost products sold within next two years notional amount outstanding foreign currency forward contracts primarily attributed euro million japanese yen million december fair value foreign currency forward contract attributed japanese yen notional amount million designated cash flow hedge million included prepaid expenses december cash flow hedge accounting discontinued forecasted transaction longer probable occurring within days originally forecasted date hedge longer effective assessments determine whether derivatives designated qualifying hedges highly effective offsetting changes cash flows hedged items performed inception quarterly basis earnings impact related discontinued cash flow hedges hedge ineffectiveness significant periods presented net investment hedges nonus dollar borrowings million million designated hedge foreign currency exposures net investment certain foreign affiliates borrowings designated net investment hedges recognized long term debt effective portion foreign exchange gains losses remeasurement debt recognized foreign currency translation component accumulated oci related offset long term debt fair value hedges fixedtofloating interest rate swap contracts designated fair value hedges used interest rate risk management strategy create appropriate balance fixed floating rate debt contracts underlying debt hedged benchmark risk recorded fair value effective interest rate contracts onemonth libor december plus interest rate spread ranging underlying swap terminated prior maturity fair value basis adjustment underlying debt instrument amortized reduction interest expense remaining life debt notional amount fixedtofloating interest rate swap contracts executed million billion notional amount fixedto floating interest rate swap contracts terminated million generating proceeds million including accrued interest million additional contracts terminated connection debt redemptions debt obligations shortterm borrowings million million december respectively consisting primarily bank overdrafts longterm debt current portion longterm debt includes december dollars millions principal value euro notes due notes due notes due notes due euro notes due notes due debentures due notes due debentures due notes due notes due notes due notes due debentures due maturing subtotal adjustments principal value fair value interest rate swap contracts unamortized basis adjustment swap terminations unamortized bond discounts total current portion longterm debta longterm debt included liabilities related assets heldforsale december fair value longterm debt million million december respectively estimated based upon quoted market prices similar debt instruments fair value shortterm borrowings approximates carrying value due short maturities debt instruments floating rate convertible senior debentures million due redeemable holders par september fundamental change ownership occurs callable par time bms debentures current conversion price equal conversion rate shares principal amount subject certain antidilutive adjustments senior unsecured notes issued registered public offerings billion billion interest notes paid semiannually notes rank equally right payment bmss existing future senior unsecured indebtedness redeemable bms whole part time predetermined redemption price notes principal amount million matured repaid substantially billion debt obligations assumed acquisition amylin repaid including promissory note lilly respect revenue sharing obligation amylin senior notes due debt redemptions debt redemption activity including repayment amylin debt obligations follows dollars millions principal amount carrying value redemption price notional amount interest rate swap contracts terminated swap termination proceedspayments total loss interest payments million million million net amounts received interest rate swap contracts two separate billion fiveyear revolving credit facilities maintained syndicate lenders facilities provide customary terms conditions financial covenants extendable anniversary date consent lenders borrowings outstanding either revolving credit facility december financial guarantees provided form standby letters credit performance bonds million december standby letters credit issued financial institutions support guarantees various obligations performance bonds issued support range ongoing operating activities including sale products hospitals foreign ministries health bonds customs duties value added tax guarantees related miscellaneous legal actions significant majority outstanding financial guarantees expire within year expected funded note receivables december dollars millions trade receivables less allowances net trade receivables alliance partners receivables prepaid refundable income taxes miscellaneous receivables receivables nonus receivables sold nonrecourse basis million million million aggregate receivables three pharmaceutical wholesalers us represented total trade receivables december respectively changes allowances bad debt chargebacks cash discounts follows year ended december dollars millions balance beginning year provision utilization assets heldforsale balance end year note inventories december dollars millions finished goods work process raw packaging materials inventories inventories expected remain onhand beyond one year million december million december included assets note property plant equipment december dollars millions land buildings machinery equipment fixtures construction progress gross property plant equipment less accumulated depreciation property plant equipment property plant equipment related mount vernon indiana manufacturing facility approximately million december facility expected sold included assets heldforsale periods assets available immediate sale present condition see note alliances discussion sale diabetes business depreciation expense million million million note goodwill intangible assets december estimated dollars millions useful lives goodwill intangible assets licenses years developed technology rights years capitalized software years inprocess research development iprd gross intangible assets less accumulated amortization total intangible assets goodwill million allocated sale diabetes business including million presented assets heldforsale december seenote assets heldforsale discussion amortization expense million million million future annual amortization expense intangible assets expected approximately million million million million million million thereafter intangible asset impairment charges million none billion million iprd impairment charge recognized peginterferon lambda phase iii development treatment hepatitis c virus hcv full writeoff required assessing potential commercial viability asset estimating fair value assessment considered lower likelihood filing registration certain markets completing revised projections revenues expenses significant decline prior projected revenues resulted global introduction oral noninterferon products used treat patients hcv alternative uses product bms announced discontinued development bms formerly known inx nucleotide polymerase nsb inhibitor phase ii development treatment hcv august decision made interest patient safety based rapid thorough ongoing assessment patients phase ii study voluntarily suspended august bms acquired bms acquisition inhibitex february result termination development program billion pretax impairment charge recognized impairment charge million also recognized related continued competitive pricing pressures partial writedown fair value developed technology rights related previously acquired nonkey product note accrued expenses december dollars millions employee compensation benefits royalties accrued research development restructuring current pension postretirement benefits accrued litigation total accrued expenses note sales rebates return accruals reductions trade receivables accrued rebates returns liabilities follows december dollars millions chargebacks related government programs cash discounts reductions trade receivables managed healthcare rebates contract discounts medicaid rebates sales returns adjustments accrued rebates returns note deferred income december dollars millions alliances note gain saleleaseback transactions total deferred income current portion noncurrent portion alliances include unamortized amounts upfront milestone licensing proceeds revenue deferrals attributed gilead alliance undelivered elements diabetes business divestiture upfront milestone licensing proceeds amortized shorter contractual rights period expected life product deferred gains saleleaseback transactions amortized remaining lease terms related facilities deferrals include approximately million invoiced product early access program eu portion amount recognized revenue subject final price negotiations local government amortization deferred income million million million deferred income million included liabilities related assets heldforsale december seenote assets heldforsale discussion note equity common stock capital treasury stock excess par value retained noncontrolling dollars shares millions shares par value stock earnings shares cost interest balance january net earnings cash dividends declared stock repurchase program employee stock compensation plans comprehensive income attributable noncontrolling interest distributions balance december net earnings cash dividends declared stock repurchase program employee stock compensation plans distributions balance december net earnings cash dividends declared employee stock compensation plans debt conversion variable interest entity distributions balance december treasury stock recognized cost reacquire shares shares issued treasury recognized utilizing firstin firstout method noncontrolling interest primarily related plavix avaproavalide partnerships sanofi territory covering americas net earnings attributable noncontrolling interest presented net taxes million million million corresponding increase provision income taxes distribution partnership profits sanofi sanofis funding ongoing partnership operations occur routine basis activity includes pretax income distributions related partnerships components comprehensive incomeloss follows dollars millions pretax tax tax derivatives qualifying cash flow hedgesa unrealized gains reclassified net earnings derivatives qualifying cash flow hedges pension postretirement benefits actuarial losses amortizationb settlements curtailmentsc pension postretirement benefits availableforsale securities unrealized gains realized gainsd availableforsale securities foreign currency translation derivatives qualifying cash flow hedgesa unrealized gains reclassified net earnings derivatives qualifying cash flow hedges pension postretirement benefits actuarial gains amortizationb settlementsc pension postretirement benefits availableforsale securities unrealized losses realized gainsd availableforsale securities foreign currency translation derivatives qualifying cash flow hedgesa unrealized gains reclassified net earnings derivatives qualifying cash flow hedges pension postretirement benefits actuarial losses amortizationb settlements curtailmentsc pension postretirement benefits availableforsale securities unrealized gains realized gainsd availableforsale securities foreign currency translation reclassifications net earnings derivatives qualifying effective hedges recognized costs products sold b actuarial gainslosses prior service costcredits amortized cost products sold research development marketing selling administrative expenses c pension settlements curtailments recognized incomeexpense realized gains availableforsale securities recognized incomeexpense accumulated balances related component comprehensive incomeloss net taxes follows december dollars millions derivatives qualifying cash flow hedges pension postretirement benefits availableforsale securities foreign currency translation accumulated comprehensive loss note pension postretirement postemployment liabilities bms sponsors defined benefit pension plans defined contribution plans termination indemnity plans regular fulltime employees principal defined benefit pension plan bristolmyers squibb retirement income plan covering us employees representing approximately consolidated pension plan assets obligations bms contributes least minimum amount required employee retirement income security act erisa plan benefits based primarily participants years credited service final average compensation plan assets consist principally equity fixedincome securities comprehensive medical group life benefits provided substantially us retirees electing participate comprehensive medical group life plans medical plan contributory contributions adjusted periodically vary date retirement life insurance plan noncontributory plan assets consist principally equity fixedincome securities net periodic benefit costcredit defined benefit pension postretirement benefit plans includes pension benefits benefits dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets amortization prior service credits amortization net actuarial gainloss curtailments settlements special termination benefits net periodic benefit costcredit september bms fiduciary counselors inc independent fiduciary bristolmyers squibb company retirement income plan entered definitive agreement transfer certain us pension assets prudential insurance company america prudential settle approximately billion pension obligations bms purchased group annuity contract prudential december irrevocably assumed obligation make future annuity payments certain bms retirees transaction change amount monthly pension benefit received affected retirees surviving beneficiaries resulted pretax settlement charge million pension settlement charges also recognized determining annual lump sum payments exceed annual interest service costs certain pension plans including primary us pension plan changes defined benefit postretirement benefit plan obligations assets funded status amounts recognized consolidated balance sheets follows pension benefits benefits dollars millions benefit obligations beginning year service costbenefits earned year interest cost plan participants contributions curtailments settlements plan amendments actuarial gainslosses retiree drug subsidy benefits paid exchange rate gainslosses benefit obligations end year fair value plan assets beginning year actual return plan assets employer contributions plan participants contributions settlements retiree drug subsidy benefits paid exchange rate gainslosses fair value plan assets end year funded status assetsliabilities recognized assets accrued expenses pension postretirement liabilities funded status recognized accumulated comprehensive loss net actuarial gainslosses prior service credit total accumulated benefit obligation defined benefit pension plans million million december respectively additional information related pension plans follows dollars millions pension plans projected benefit obligations excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation fair value plan assets actuarial assumptions weightedaverage assumptions used determine benefit obligations december follows pension benefits benefits discount rate rate compensation increase weightedaverage actuarial assumptions used determine net periodic benefit creditcost years ended december follows pension benefits benefits discount rate expected longterm return plan assets rate compensation increase yield high quality corporate bonds matching duration benefit obligations used determining discount rate citigroup pension discount curve used developing discount rate us plans expected return plan assets determined using expected rate return calculated value assets referred marketrelated value fair value plan assets exceeded marketrelated value million december differences assumed actual returns amortized marketrelated value straightline basis threeyear period several factors considered developing expected return plan assets including long term historical returns input external advisors individual asset class return forecasts developed based upon market conditions example price earnings levels yields longterm growth expectations expected longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualized returns us pension plans follows years years years actuarial gains losses resulted changes actuarial assumptions changes discount rate revised mortality rates differences assumed actual experience differences actual expected return plan assets gains losses amortized life expectancy plan participants us plans years expected remaining service periods plans extent exceed higher marketrelated value projected benefit obligation respective plan amortization net actuarial loss prior service credit expected approximately million periodic benefit cost credit included cost products sold research development marketing selling administrative expenses except curtailments settlements special termination benefits included expenses assumed healthcare cost trend rates december follows healthcare cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend rate year rate reaches ultimate trend rate assumed healthcare cost trend rates effect amounts reported healthcare plans onepercentagepoint change assumed healthcare cost trend rates would material impact service interest cost post retirement benefit obligation plan assets fair value pension postretirement plan assets asset category december follows december december dollars millions level level level total level level level total equity securities equity funds fixed income funds corporate debt securities venture capital limited partnerships government mortgage backed securities us treasury agency securities shortterm investment funds insurance contracts event driven hedge funds state municipal bonds real estate cash cash equivalents total plan assets fair value investment valuation policies per investment class follows level inputs utilize quoted prices unadjusted active markets accessible measurement date identical assets liabilities fair value hierarchy gives highest priority level inputs instruments include equity securities equity funds real estate funds fixed income funds publicly traded national securities exchange cash cash equivalents cash cash equivalents highly liquid investments original maturities three months less time purchase recognized cost approximates fair value pending trade sales purchases included cash cash equivalents final settlement level inputs include observable prices similar instruments quoted prices identical similar instruments markets active observable inputs corroborated market data substantially full term assets liabilities equity funds fixed income funds event driven hedge funds shortterm investment funds classified level within fair value hierarchy valued net asset value shares held year end significant unfunded commitments restrictions redemptions related investments valued nav december corporate debt securities government mortgage backed securities us treasury agency securities state municipal bonds classified level within fair value hierarchy valued utilizing observable prices similar instruments quoted prices identical similar instruments markets active level unobservable inputs used little market data available venture capital limited partnerships classified level within fair value hierarchy invest underlying securities whose market values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs used valuation methodologies include discount rates earning interest taxes depreciation amortization ebitda multiples revenue multiples significant changes inputs could result significantly lower higher fair value measurements insurance contract interests carried contract value approximates estimated fair value based fair value underlying investment insurance company insurance contracts held certain foreign pension plans following summarizes activity financial assets utilizing level fair value measurements venture capital limited insurance dollars millions partnerships contracts total fair value january purchases sales settlements net realized gainslosses unrealized gainslosses fair value december purchases sales settlements net realized gainslosses unrealized gainslosses fair value december investment strategy emphasizes equities order achieve higher expected returns lower expenses required cash contributions longterm target asset allocation public equity us international global private equity longduration fixed income maintained us pension plans investments diversified within three major asset categories approximately us pension plans equity investments actively managed venture capital limited partnerships typically valued three month lag using latest available information bms common stock represents less plan assets december contributions estimated future benefit payments contributions pension plans million million million expected approximately million estimated annual future benefit payments including lump sum payments range million million next five years aggregate billion subsequent five year period savings plans principal defined contribution plan bristolmyers squibb savings investment program contribution based employee contributions level company match expense attributed defined contribution plans us million note employee stock benefit plans may shareholders approved stock award incentive plan plan replaced stock incentive plan shares common stock reserved issuance pursuant stock plans options conversions preferred stock million december shares available granted active plans million december shares issued treasury stock shares tendered prior year pay purchase price options shares previously utilized satisfy withholding tax obligations upon exercise continue available reserved executive officers key employees may granted options purchase common stock less market price date option granted options generally become exercisable ratably four years maximum term ten years plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price company granted stock options stock appreciation rights since common stock stock units may granted key employees subject restrictions continuous employment generally vesting occurs ratably four year period grant date compensation expense recognized vesting period stock unit right receive stock end specified vesting period voting rights market share units granted executives vesting conditioned upon continuous employment vesting date payout factor least share price award date payout factor share price vesting date divided share price award date maximum share price used payout factor calculated using average closing prices grant vest date nine trading days immediately preceding grant vest date vesting occurs ratably four years performance share units granted executives three year cycle granted target number units subject adjustment based company performance shares ultimately issued awards granted prior calculated based actual performance compared earnings targets performance criteria established beginning year three year performance cycle shares ultimately issued awards granted based actual performance compared earnings target performance criteria established subsequent adjustment company 's threeyear total shareholder return relative peer group companies vesting occurs third anniversary grant date stockbased compensation expense awards ultimately expected vest recognized vesting period acceleration unvested stock options restricted stock units connection acquisition amylin resulted stockbased compensation expense forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates information related stockbased compensation benefits follows years ended december dollars millions stock options restricted stock units market share units performance share units amylin stock options restricted stock units see note total stockbased compensation expense income tax benefit stock options restricted stock units market share units performance share units weighted number weighted number weighted number weighted number average average average average options exercise price nonvested grantdate nonvested grantdate nonvested grantdate shares thousands outstanding shares awards fair value awards fair value awards fair value balance january granted releasedexercised adjustments actual payout forfeitedcanceled balance december vested expected vest restricted market performance dollars millions stock units share units share units unrecognized compensation cost expected weightedaverage period years compensation cost recognized amounts millions except per share data weightedaverage grant date fair value per share restricted stock units market share units performance share units fair value options awards vested year stock options restricted stock units market share units performance share units total intrinsic value stock options exercised year fair value awards approximates closing trading price bms 's common stock grant date fair value market share units also considers payout formula probability satisfying market conditions following table summarizes significant ranges outstanding exercisable options december amounts millions except per share data options outstanding exercisable number weightedaverage weightedaverage outstanding exercisable remaining contractual exercise price aggregate range exercise prices thousands life years per share intrinsic value aggregate intrinsic value preceding table represents total pretax intrinsic value based closing stock price december note leases annual minimum rental commitments noncancelable operating leases primarily real estate motor vehicles approximately million next five years aggregate million thereafter operating lease expenses million million million sublease income material periods presented note legal proceedings contingencies company certain subsidiaries involved various lawsuits claims government investigations legal proceedings arise ordinary course business company recognizes accruals contingencies probable liability incurred amount loss reasonably estimated matters involve patent infringement antitrust securities pricing sales marketing practices environmental commercial health safety matters consumer fraud employment matters product liability insurance coverage legal proceedings material company believes could become material described although company believes substantial defenses matters assurance increase scope pending matters future lawsuits claims government investigations legal proceedings material unless otherwise noted company unable assess outcome respective litigation able provide estimated range potential loss furthermore failure enforce patent rights would likely result substantial decreases respective product revenues generic competition intellectual property baraclude august teva filed anda manufacture market generic versions baraclude company received paragraph iv certification letter teva challenging one orange booklisted patent baraclude us patent patent covering entecavir molecule september company filed patent infringement lawsuit us district court district delaware delaware district court teva infringement february delaware district court ruled company invalidated patent company appealed delaware district courts decision june us court appeals federal circuit federal court appeals denied company 's appeal july company filed petition en banc rehearing entire federal court appeals denied october january company filed petition writ certiorari us supreme court requesting court hear appeal federal court appeals decision september teva received final approval fda generic version entecavir launched product us experienced rapid significant negative impact us net product sales baraclude beginning fourth quarter us net product sales baraclude million baraclude south korea daewoong pharmaceutical co ltd hanmi pharmaceuticals co ltd initiated separate invalidity actions korean intellectual property office korean patent patent patent expires october korean equivalent patent us composition matter patent january korean intellectual property tribunal ruled ' patent valid still remains risk generic companies continue challenge validity ' patent andor launch generic versions baraclude prior october net product sales baraclude south korea million plavix australia previously disclosed sanofi notified august genrx proprietary limited genrx obtained regulatory approval application clopidogrel bisulfate mg tablets australia genrx formerly subsidiary apotex inc apotex since changed name apotex august apotex filed application federal court australia federal court seeking revocation sanofis australian patent case nsd sanofi filed counterclaims infringement sought injunction september federal court granted sanofis injunction subsidiary company subsequently added party proceedings february second company spirit pharmaceuticals pty ltd also filed revocation suit patent case consolidated apotex case trial occurred april august federal court australia held claims patent covering clopidogrel bisulfate hydrochloride hydrobromide taurocholate salts valid federal court also held process claims pharmaceutical composition claims claim directed clopidogrel pharmaceutically acceptable salts invalid company sanofi filed notices appeal full court federal court australia full court appealing holding invalidity claim covering clopidogrel pharmaceutically acceptable salts process claims pharmaceutical composition claims stayed federal courts ruling apotex filed notice appeal appealing holding validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claims hearing appeals occurred february september full court held claims patent invalid november company sanofi applied high court australia high court special leave appeal judgment full court march high court denied company sanofis request hear appeal full court decision case remanded federal court proceedings related damages sought apotex australian government intervened matter also seeking damages alleged losses experienced period injunction place company apotex settled apotex case case dismissed australian government 's claim still pending possible time predict outcome australian governments claim impact company plavix canada apotex inc april apotex filed impeachment action sanofi federal court canada alleging sanofis canadian patent patent invalid june sanofi filed defense impeachment action filed suit apotex infringement patent trial completed june december federal court canada issued decision patent invalid july federal court appeal reversed federal court canada 's decision upheld validity ' patent case remanded federal court canada consider damages owed company apotex infringement patent september apotex sought leave appeal decision federal court appeal supreme court canada supreme court canada scheduled hear case november company apotex settled case dismissed thus concluding matter general commercial litigation remaining apotex matter related plavix previously disclosed january apotex filed lawsuit florida state court broward county alleging breach contract relating may proposed settlement agreement apotex relating pending plavix patent litigation trial held march jury verdict delivered favor company apotex appealed decision company apotex settled apotex withdrawn appeal thus concluding matter pricing sales promotional practices litigation investigations abilify federal subpoena january company received subpoena united states attorneys office sdny requesting information related among things sales marketing abilify possible time assess outcome matter potential impact company abilify state attorneys general investigation march company received letter delaware attorney generals office advising multistate coalition investigating whether certain abilify marketing practices violated respective states consumer protection statutes company entered tolling agreement states possible time reasonably assess outcome investigation awp litigation previously disclosed company together number pharmaceutical manufacturers defendant number private class actions well suits brought attorneys general various states actions plaintiffs allege defendants caused average wholesale prices awps products inflated thereby injuring government programs entities persons reimbursed prescription drugs based awps company remains defendant two state attorneys general suits pending state courts pennsylvania wisconsin beginning august company defendant trial commonwealth court pennsylvania commonwealth court brought commonwealth pennsylvania september jury issued verdict company finding company liable fraudulent negligent misrepresentation however commonwealth court judge issued decision pennsylvania consumer protection claim go jury finding company liable million enjoining company contributing provision inflated awps company appealed decision pennsylvania supreme court oral argument took place may june pennsylvania supreme court vacated commonwealth judge 's decision remanded matter back commonwealth court january commonwealth court entered judgment favor company possible commonwealth pennsylvania could appeal decision qui tam litigation march company served unsealed qui tam complaint filed three former sales representatives california superior court county los angeles california department insurance elected intervene lawsuit complaint alleges company paid kickbacks california providers pharmacies violation california insurance frauds prevention act cal ins code possible time reasonably assess outcome lawsuit impact company plavix state attorneys general lawsuits company certain affiliates sanofi defendants consumer protection andor false advertising actions brought several states relating sales promotion plavix possible time reasonably assess outcome lawsuits potential impact company product liability litigation company party various product liability lawsuits previously disclosed addition lawsuits company also faces unfiled claims involving products plavix previously disclosed company certain affiliates sanofi defendants number individual lawsuits various state federal courts claiming personal injury damage allegedly sustained using plavix currently claims involving injury plaintiffs well claims spouses andor beneficiaries filed state federal courts various states including california illinois new jersey delaware new york february judicial panel multidistrict litigation granted company sanofis motion establish multidistrict litigation coordinate federal pretrial proceedings plavix product liability related cases new jersey federal court possible time reasonably assess outcome lawsuits potential impact company reglan company one number defendants numerous lawsuits behalf approximately plaintiffs including injury plaintiffs claiming personal injury allegedly sustained using reglan another brand generic drug metoclopramide product indicated gastroesophageal reflux certain gastrointestinal disorders well claims spouses andor beneficiaries company generic subsidiary apothecon inc distributed metoclopramide tablets manufactured another party possible time reasonably assess outcome lawsuits resolution pending lawsuits however expected material impact company byetta amylin former subsidiary company lilly codefendants product liability litigation related byetta date separate lawsuits pending behalf active plaintiffs including pending settlements include injury plaintiffs well claims spouses andor beneficiaries various courts us company agreed principle resolve claims majority cases brought individuals allege personal injury sustained using byetta primarily pancreatic cancer pancreatitis cases claiming alleged wrongful death majority cases pending federal court san diego recently established multidistrict litigation next largest contingent cases pending coordinated proceeding california superior court los angeles amylin product liability insurance covering substantial number claims involving byetta additional liability amylin respect byetta expected shared company astrazeneca possible reasonably predict outcome lawsuit claim proceeding potential impact company environmental proceedings previously reported company party several environmental proceedings matters responsible various state federal foreign laws including comprehensive environmental response compensation liability act cercla certain costs investigating andor remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated third parties cercla matters respect cercla matters company responsible various state federal foreign laws company typically estimates potential costs based information obtained us environmental protection agency counterpart state foreign agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties company accrues liabilities probable reasonably estimable company estimated share future costs sites million december represents sum best estimates best estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties new brunswick facilityenvironmental personal injury lawsuits since may lawsuits filed company new jersey superior court behalf current former residents new brunswick new jersey live lived adjacent companys new brunswick facility complaints allege various personal injuries resulting environmental contamination new brunswick facility historical operations site claims medical monitoring portion complaints also assert claims alleged property damage october new jersey supreme court granted mass tort status cases transferred new jersey superior court atlantic county centralized case management purposes since october additional cases filed new jersey superior court removed company united states district court district new jersey accordingly excess cases state federal court actions june company plaintiffs agreed settlement finalized december concludes matter north brunswick township board education previously disclosed october company contacted counsel representing north brunswick nj board education boe regarding site waste materials er squibb sons may disposed fill material containing industrial waste heavy metals excess residential standards discovered expansion project north brunswick township high school well number neighboring residential properties adjacent public park areas january new jersey department environmental protection njdep sent company others information request letter possible waste disposal site company responded march boe township current owners school property park conducting jointly financing soil remediation work ground water investigation work work plan approved njdep asked company contribute cost company actively monitoring cleanup project including costs date neither school board township asserted claim company instead company local entities negotiated agreement attempt resolve matter informal means avoid litigation central component agreement provision company interim funding help defray cleanup costs assure work interrupted company transmitted interim funding payments december november parties commenced mediation late however efforts successful parties moved binding allocation process parties expected conduct fact expert discovery followed formal evidentiary hearings written argument addition september township boe filed suits several parties alleged contributed waste materials site litigation settled parties company currently believe responsible additional amounts beyond two interim payments totaling million already transmitted additional possible loss expected material proceedings sec germany investigation october sec informed company begun formal inquiry activities certain companys german pharmaceutical subsidiaries employees andor agents secs inquiry encompasses matters formerly investigation german prosecutor munich germany since resolved company understands inquiry concerns potential violations foreign corrupt practices act fcpa company cooperating sec fcpa investigation march company received subpoena sec issued connection investigation fcpa primarily relating sales marketing practices various countries company cooperating sec along department justice investigation matters particular company investigating certain sales marketing practices china possible time assess outcome matters potential impact company note selected quarterly financial data unaudited dollars millions except per share data first quarter second quarter third quarter fourth quarter year total revenues gross margin net earnings net earningsloss attributable noncontrolling interest bms earnings per share basica earnings per share diluteda cash dividends declared per common share cash cash equivalents marketable securitiesb total assets longterm debt equity dollars millions except per share data first quarter second quarter third quarter fourth quarter year total revenues gross margin net earnings net earningsloss attributable noncontrolling interest bms earnings per share basica earnings per share diluteda cash dividends declared per common share cash cash equivalents marketable securitiesb total assets longterm debtc equity earnings per share quarters may add amounts year period computed discrete basis b marketable securities includes current noncurrent assets c also includes current portion longterm debt following specified items affected comparability results first second third fourth dollars millions quarter quarter quarter quarter year cost products solda additional year branded prescription drug fee process standardization implementation costs marketing selling administrative upfront milestone payments iprd impairments research development provision restructuring gain sale product lines businesses assets pension curtailments settlements special termination benefits acquisition alliance related itemsb litigation chargesrecoveries loss debt redemption outlicensed intangible asset impairment upfront milestone licensing receipts incomeexpense increasedecrease pretax income income tax items specified tax chargec income taxes increasedecrease net earnings specified items cost products sold accelerated depreciation asset impairment shutdown costs b includes million additional year branded prescription drug fee third quarter c specified tax charge relates transfer pricing matters first second third fourth dollars millions quarter quarter quarter quarter year accelerated depreciation asset impairment shutdown costs amortization acquired amylin intangible assets amortization amylin alliance proceeds amortization amylin inventory adjustment cost products sold marketing selling administrativea research developmentb provision restructuring pension settlements acquisition alliance related items litigation recoveries upfront milestone licensing receipts incomeexpense increase pretax income income tax items increase net earnings specified items marketing selling administrative process standardization implementation costs b specified items research development upfront milestone licensing payments report independent registered public accounting firm board directors shareholders bristolmyers squibb company audited accompanying consolidated balance sheets bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive income cash flows three years period ended december financial statements responsibility companys management responsibility express opinion financial statements based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position bristolmyers squibb company subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also audited accordance standards public company accounting oversight board united states companys internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion companys internal control financial reporting deloitte touche llp parsippany new jersey february item changes disagreements accountants accounting financial disclosure none item controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures term defined exchange act rule ae based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report issued report effectiveness companys internal control financial reporting december included herein changes internal control financial reporting changes company 's internal control financial reporting quarter ended december materially affected reasonable likely materially affect company 's internal control financial reporting item b information none report independent registered public accounting firm board directors shareholders bristolmyers squibb company audited internal control financial reporting bristolmyers squibb company subsidiaries company december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed supervision companys principal executive principal financial officers persons performing similar functions effected companys board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion company maintained material respects effective internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission also audited accordance standards public company accounting oversight board united states consolidated financial statements year ended december company report dated february expressed unqualified opinion consolidated financial statements deloitte touche llp parsippany new jersey february part iii item directors executive officers registrant reference made proxy statement filed march respect directors registrant incorporated herein reference made part hereof response information required item b information required item respect executive officers registrant included part ia reliance general instruction g instruction item b regulation sk item executive compensation reference made proxy statement filed march respect executive compensation incorporated herein reference made part hereof response information required item item security ownership certain beneficial owners management related stockholder matters reference made proxy statement filed march respect security ownership certain beneficial owners management incorporated herein reference made part hereof response information required item item certain relationships related transactions reference made proxy statement filed march respect certain relationships related transactions incorporated herein reference made part hereof response information required item item auditor fees reference made proxy statement filed march respect auditor fees incorporated herein reference made part hereof response information required item part iv item